



## Clinical trial results:

### A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects who have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Summary

|                          |                |
|--------------------------|----------------|
| EudraCT number           | 2016-004288-37 |
| Trial protocol           | BE             |
| Global end of trial date | 22 July 2021   |

#### Results information

|                                |                |
|--------------------------------|----------------|
| Result version number          | v1 (current)   |
| This version publication date  | 09 August 2022 |
| First version publication date | 09 August 2022 |

#### Trial information

##### Trial identification

|                       |         |
|-----------------------|---------|
| Sponsor protocol code | NOR-213 |
|-----------------------|---------|

##### Additional study identifiers

|                                    |                 |
|------------------------------------|-----------------|
| ISRCTN number                      | -               |
| ClinicalTrials.gov id (NCT number) | NCT03039790     |
| WHO universal trial number (UTN)   | U1111-1189-7907 |

Notes:

#### Sponsors

|                              |  |
|------------------------------|--|
| Sponsor organisation name    | HilleVax   |
| Sponsor organisation address | Blvd Lilienthal 42, Glattpark-Opfikon (Zurich), Switzerland, 8152      |
| Public contact               | Paul Bavier, HilleVax, +1 6172063351, pbavier@hillevax.com             |
| Scientific contact           | Astrid Borkowski, HilleVax, +41 (0) 799069941, aborkowski@hillevax.com |

Notes:

#### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|  |              |
|--|--------------|
| Analysis stage                                       | Final        |
| Date of interim/final analysis                       | 04 July 2022 |
| Is this the analysis of the primary completion data? | No           |

|                                  |              |
|----------------------------------|--------------|
| Global end of trial reached?     | Yes          |
| Global end of trial date         | 22 July 2021 |
| Was the trial ended prematurely? | No           |

Notes:

## General information about the trial

Main objective of the trial:

The main objective of the trial is to evaluate the humoral response after at least 1 dose of NoV vaccine up to 5 years after intramuscular (IM injection as measured by histo-blood group antigen (HBGA) blocking assay.

Protection of trial subjects:

All the participants were required to read and sign the Informed Consent Form (ICF).

Background therapy: -

Evidence for comparator: -

|   |                  |
|---|------------------|
| Actual start date of recruitment                          | 20 February 2017 |
| Long term follow-up planned                               | No               |
| Independent data monitoring committee (IDMC) involvement? | No               |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                    |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Belgium: 345       |
| Country: Number of subjects enrolled | United States: 183 |
| Worldwide total number of subjects   | 528                |
| EEA total number of subjects         | 345                |

Notes:

### Subjects enrolled per age group

|   |     |
|---|-----|
| In utero                                  | 0   |
| Preterm newborn - gestational age < 37 wk | 0   |
| Newborns (0-27 days)                      | 0   |
| Infants and toddlers (28 days-23 months)  | 0   |
| Children (2-11 years)                     | 0   |
| Adolescents (12-17 years)                 | 0   |
| Adults (18-64 years)                      | 405 |
| From 65 to 84 years                       | 86  |
| 85 years and over                         | 37  |

## Subject disposition

### Recruitment

Recruitment details:

Participants took part in the study at 11 investigational sites in Belgium (9 sites) and the United States (2 sites) from 21 February 2017 to 22 July 2021.

### Pre-assignment

Screening details:

Healthy volunteers who previously received NoV vaccine in studies NOR-107 (NCT02038907), NOR-210 (NCT02475278) and NOR-204 (NCT02661490) were assessed in this study for up to 5 years. No additional doses of vaccine were administered.

### Period 1

|                              |                                |
|------------------------------|--------------------------------|
| Period 1 title               | Overall Study (overall period) |
| Is this the baseline period? | Yes                            |
| Allocation method            | Randomised - controlled        |
| Blinding used                | Not blinded                    |

### Arms

|                              |  |
|------------------------------|--|
| Are arms mutually exclusive? | Yes  |
| <b>Arm title</b>             | NOR-107: GI.1/GII.4 (15/15/500) µg- MPL 50 µg,1-Dose |

Arm description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus virus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|  |  |
|--|--|
| Arm type                               | Experimental   |
| Investigational medicinal product name | Norovirus Bivalent Virus-Like Particle (VLP) Vaccine |
| Investigational medicinal product code |  |
| Other name                             |  |
| Pharmaceutical forms                   | Solution for injection                               |
| Routes of administration               | Intramuscular use                                    |

Dosage and administration details:

Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

|  |                          |
|--|--------------------------|
| Investigational medicinal product name | Hepatitis A Vaccine      |
| Investigational medicinal product code |                          |
| Other name                             | Havrix                   |
| Pharmaceutical forms                   | Suspension for injection |
| Routes of administration               | Intramuscular use        |

Dosage and administration details:

Hepatitis A vaccine, intramuscular injection (IM)

|                  |  |
|------------------|--|
| <b>Arm title</b> | NOR-107: GI.1/GII.4 (15/50/500) µg- MPL 50 µg,1-Dose |
|------------------|--|

Arm description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|  |                          |
|--|--------------------------|
| Arm type                               | Experimental             |
| Investigational medicinal product name | Hepatitis A Vaccine      |
| Investigational medicinal product code |                          |
| Other name                             | Havrix                   |
| Pharmaceutical forms                   | Suspension for injection |
| Routes of administration               | Intramuscular use        |

|   |  |
|---|--|
| Dosage and administration details:  |  |
| Hepatitis A vaccine, intramuscular injection (IM)   |  |
| Investigational medicinal product name  | Norovirus Bivalent Virus-Like Particle (VLP) Vaccine |
| Investigational medicinal product code  |  |
| Other name  |  |
| Pharmaceutical forms  | Solution for injection                               |
| Routes of administration  | Intramuscular use                                    |
| Dosage and administration details:  |  |
| Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection  |  |
| <b>Arm title</b>  | NOR-107: GI.1/GII.4 (50/50/500) µg- MPL 50 µg,1-Dose |
| Arm description:  |  |
| Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study. |  |
| Arm type  | Experimental   |
| Investigational medicinal product name  | Hepatitis A Vaccine                                  |
| Investigational medicinal product code  |  |
| Other name  | Havrix   |
| Pharmaceutical forms  | Suspension for injection                             |
| Routes of administration  | Intramuscular use                                    |
| Dosage and administration details:  |  |
| Hepatitis A vaccine, intramuscular injection (IM)   |  |
| Investigational medicinal product name  | Norovirus Bivalent Virus-Like Particle (VLP) Vaccine |
| Investigational medicinal product code  |  |
| Other name  |  |
| Pharmaceutical forms  | Solution for injection                               |
| Routes of administration  | Intramuscular use                                    |
| Dosage and administration details:  |  |
| Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection  |  |
| <b>Arm title</b>  | NOR-107: GI.1/GII.4 (15/15/500) µg- MPL 15 µg,1-Dose |
| Arm description:  |  |
| Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study. |  |
| Arm type  | Experimental   |
| Investigational medicinal product name  | Hepatitis A Vaccine                                  |
| Investigational medicinal product code  |  |
| Other name  | Havrix   |
| Pharmaceutical forms  | Suspension for injection                             |
| Routes of administration  | Intramuscular use                                    |
| Dosage and administration details:  |  |
| Hepatitis A vaccine, intramuscular injection (IM)   |  |
| Investigational medicinal product name  | Norovirus Bivalent Virus-Like Particle (VLP) Vaccine |
| Investigational medicinal product code  |  |
| Other name  |  |
| Pharmaceutical forms  | Solution for injection                               |
| Routes of administration  | Intramuscular use                                    |
| Dosage and administration details:  |  |
| Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection  |  |
| <b>Arm title</b>  | NOR-107: GI.1/GII.4 (15/50/500) µg- MPL 15 µg,1-Dose |

**Arm description:**

Eligible NOR-107 participants who had received IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|  |  |
|--|--|
| Arm type                               | Experimental   |
| Investigational medicinal product name | Norovirus Bivalent Virus-Like Particle (VLP) Vaccine |
| Investigational medicinal product code |  |
| Other name                             |  |
| Pharmaceutical forms                   | Solution for injection                               |
| Routes of administration               | Intramuscular use                                    |

**Dosage and administration details:**

Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

|  |                          |
|--|--------------------------|
| Investigational medicinal product name | Hepatitis A Vaccine      |
| Investigational medicinal product code |                          |
| Other name                             | Havrix                   |
| Pharmaceutical forms                   | Suspension for injection |
| Routes of administration               | Intramuscular use        |

**Dosage and administration details:**

Hepatitis A vaccine, intramuscular injection (IM)

|                  |  |
|------------------|--|
| <b>Arm title</b> | NOR-107: GI.1/GII.4 (50/50/500) µg- MPL 15 µg,1-Dose |
|------------------|--|

**Arm description:**

Eligible NOR-107 participants who received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|  |  |
|--|--|
| Arm type                               | Experimental   |
| Investigational medicinal product name | Norovirus Bivalent Virus-Like Particle (VLP) Vaccine |
| Investigational medicinal product code |  |
| Other name                             |  |
| Pharmaceutical forms                   | Solution for injection                               |
| Routes of administration               | Intramuscular use                                    |

**Dosage and administration details:**

Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

|  |                          |
|--|--------------------------|
| Investigational medicinal product name | Hepatitis A Vaccine      |
| Investigational medicinal product code |                          |
| Other name                             | Havrix                   |
| Pharmaceutical forms                   | Suspension for injection |
| Routes of administration               | Intramuscular use        |

**Dosage and administration details:**

Hepatitis A vaccine, intramuscular injection (IM)

|                  |   |
|------------------|---|
| <b>Arm title</b> | NOR-107: GI.1/GII.4 (15/15/500) µg,1-Dose |
|------------------|---|

**Arm description:**

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|  |                          |
|--|--------------------------|
| Arm type                               | Experimental             |
| Investigational medicinal product name | Hepatitis A Vaccine      |
| Investigational medicinal product code |                          |
| Other name                             | Havrix                   |
| Pharmaceutical forms                   | Suspension for injection |
| Routes of administration               | Intramuscular use        |

|   |  |
|---|--|
| Dosage and administration details:  |  |
| Hepatitis A vaccine, intramuscular injection (IM)   |  |
| Investigational medicinal product name  | Norovirus Bivalent Virus-Like Particle (VLP) Vaccine |
| Investigational medicinal product code  |  |
| Other name  |  |
| Pharmaceutical forms  | Solution for injection                               |
| Routes of administration  | Intramuscular use                                    |
| Dosage and administration details:  |  |
| Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection  |  |
| <b>Arm title</b>  | NOR-107: GI.1/GII.4 (15/50/500) µg,1-Dose            |
| Arm description:  |  |
| Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study. |  |
| Arm type  | Experimental   |
| Investigational medicinal product name  | Norovirus Bivalent Virus-Like Particle (VLP) Vaccine |
| Investigational medicinal product code  |  |
| Other name  |  |
| Pharmaceutical forms  | Solution for injection                               |
| Routes of administration  | Intramuscular use                                    |
| Dosage and administration details:  |  |
| Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection  |  |
| Investigational medicinal product name  | Hepatitis A Vaccine                                  |
| Investigational medicinal product code  |  |
| Other name  | Havrix   |
| Pharmaceutical forms  | Suspension for injection                             |
| Routes of administration  | Intramuscular use                                    |
| Dosage and administration details:  |  |
| Hepatitis A vaccine, intramuscular injection (IM)   |  |
| <b>Arm title</b>  | NOR-107: GI.1/GII.4 (50/50/500) µg,1-Dose            |
| Arm description:  |  |
| Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study. |  |
| Arm type  | Experimental   |
| Investigational medicinal product name  | Hepatitis A Vaccine                                  |
| Investigational medicinal product code  |  |
| Other name  | Havrix   |
| Pharmaceutical forms  | Suspension for injection                             |
| Routes of administration  | Intramuscular use                                    |
| Dosage and administration details:  |  |
| Hepatitis A vaccine, intramuscular injection (IM)   |  |
| Investigational medicinal product name  | Norovirus Bivalent Virus-Like Particle (VLP) Vaccine |
| Investigational medicinal product code  |  |
| Other name  |  |
| Pharmaceutical forms  | Solution for injection                               |
| Routes of administration  | Intramuscular use                                    |
| Dosage and administration details:  |  |
| Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection  |  |
| <b>Arm title</b>  | NOR-107: GI.1/GII.4 (50/150/500) µg,1-Dose           |

**Arm description:**

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|  |                          |
|--|--------------------------|
| Arm type                               | Experimental             |
| Investigational medicinal product name | Hepatitis A Vaccine      |
| Investigational medicinal product code |                          |
| Other name                             | Havrix                   |
| Pharmaceutical forms                   | Suspension for injection |
| Routes of administration               | Intramuscular use        |

**Dosage and administration details:**

Hepatitis A vaccine, intramuscular injection (IM)

|  |  |
|--|--|
| Investigational medicinal product name | Norovirus Bivalent Virus-Like Particle (VLP) Vaccine |
| Investigational medicinal product code |  |
| Other name                             |  |
| Pharmaceutical forms                   | Solution for injection                               |
| Routes of administration               | Intramuscular use                                    |

**Dosage and administration details:**

Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

|                  |   |
|------------------|---|
| <b>Arm title</b> | NOR-107: GI.1/GII.4 (15/50/167) µg,1-Dose |
|------------------|---|

**Arm description:**

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|  |  |
|--|--|
| Arm type                               | Experimental   |
| Investigational medicinal product name | Norovirus Bivalent Virus-Like Particle (VLP) Vaccine |
| Investigational medicinal product code |  |
| Other name                             |  |
| Pharmaceutical forms                   | Solution for injection                               |
| Routes of administration               | Intramuscular use                                    |

**Dosage and administration details:**

Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

|  |                          |
|--|--------------------------|
| Investigational medicinal product name | Hepatitis A Vaccine      |
| Investigational medicinal product code |                          |
| Other name                             | Havrix                   |
| Pharmaceutical forms                   | Suspension for injection |
| Routes of administration               | Intramuscular use        |

**Dosage and administration details:**

Hepatitis A vaccine, intramuscular injection (IM)

|                  |   |
|------------------|---|
| <b>Arm title</b> | NOR-107: GI.1/GII.4 (15/50/500) µg,2-Dose |
|------------------|---|

**Arm description:**

Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|  |  |
|--|--|
| Arm type                               | Experimental   |
| Investigational medicinal product name | Norovirus Bivalent Virus-Like Particle (VLP) Vaccine |
| Investigational medicinal product code |  |
| Other name                             |  |
| Pharmaceutical forms                   | Solution for injection                               |
| Routes of administration               | Intramuscular use                                    |

Dosage and administration details:

Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

|                  |  |
|------------------|--|
| <b>Arm title</b> | NOR-107: GI.1/GII.4 (50/150/500) µg,2-Dose |
|------------------|--|

Arm description:

Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|  |  |
|--|--|
| Arm type                               | Experimental   |
| Investigational medicinal product name | Norovirus Bivalent Virus-Like Particle (VLP) Vaccine |
| Investigational medicinal product code |  |
| Other name                             |  |
| Pharmaceutical forms                   | Solution for injection                               |
| Routes of administration               | Intramuscular use                                    |

Dosage and administration details:

Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

|                  |   |
|------------------|---|
| <b>Arm title</b> | NOR-107: GI.1/GII.4 (15/50/167) µg,2-Dose |
|------------------|---|

Arm description:

Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|  |  |
|--|--|
| Arm type                               | Experimental   |
| Investigational medicinal product name | Norovirus Bivalent Virus-Like Particle (VLP) Vaccine |
| Investigational medicinal product code |  |
| Other name                             |  |
| Pharmaceutical forms                   | Solution for injection                               |
| Routes of administration               | Intramuscular use                                    |

Dosage and administration details:

Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

|                  |  |
|------------------|--|
| <b>Arm title</b> | NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose |
|------------------|--|

Arm description:

Eligible NOR-210 participants who had received Norovirus GI.1/GII.4 bivalent VLP vaccine NoV Vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP, adjuvanted with 500 µg aluminium hydroxide), IM injection, once on Day 1 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|  |  |
|--|--|
| Arm type                               | Experimental   |
| Investigational medicinal product name | Norovirus Bivalent Virus-Like Particle (VLP) Vaccine |
| Investigational medicinal product code |  |
| Other name                             |  |
| Pharmaceutical forms                   | Solution for injection                               |
| Routes of administration               | Intramuscular use                                    |

Dosage and administration details:

Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

|                  |  |
|------------------|--|
| <b>Arm title</b> | NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose |
|------------------|--|

Arm description:

Eligible NOR-204 participants who had received Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) [15 µg of GI.1 and 50 µg of GII.4 bivalent virus-like particle (VLP)] adjuvanted with 500 µg aluminium hydroxide and 15 µg of monophosphoryl lipid A (MPL) (Composition B), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|          |              |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|



|  |                          |
|--|--------------------------|
| Investigational medicinal product name | Hepatitis A Vaccine      |
| Investigational medicinal product code |                          |
| Other name                             | Havrix                   |
| Pharmaceutical forms                   | Suspension for injection |
| Routes of administration               | Intramuscular use        |

Dosage and administration details:

Hepatitis A vaccine, intramuscular injection (IM)

|                  |   |
|------------------|---|
| <b>Arm title</b> | NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs) |
|------------------|---|

Arm description:

Eligible NOR-204 participants of age 60-94 years who had received Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus (NoV) [15 µg of GI.1 and 50 µg of GII.4 bivalent virus-like particle (VLP)] adjuvanted with 500 µg aluminium hydroxide (Composition A), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|  |                          |
|--|--------------------------|
| Arm type                               | Experimental             |
| Investigational medicinal product name | Hepatitis A Vaccine      |
| Investigational medicinal product code |                          |
| Other name                             | Havrix                   |
| Pharmaceutical forms                   | Suspension for injection |
| Routes of administration               | Intramuscular use        |

Dosage and administration details:

Hepatitis A vaccine, intramuscular injection (IM)

|                  |   |
|------------------|---|
| <b>Arm title</b> | NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs) |
|------------------|---|

Arm description:

Eligible NOR-204 participants of age 18-49 years who had received Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus (NoV) [15 µg of GI.1 and 50 µg of GII.4 bivalent virus-like particle (VLP)] adjuvanted with 500 µg aluminium hydroxide (Composition A), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|  |                          |
|--|--------------------------|
| Arm type                               | Experimental             |
| Investigational medicinal product name | Hepatitis A Vaccine      |
| Investigational medicinal product code |                          |
| Other name                             | Havrix                   |
| Pharmaceutical forms                   | Suspension for injection |
| Routes of administration               | Intramuscular use        |

Dosage and administration details:

Hepatitis A vaccine, intramuscular injection (IM)

|                  |   |
|------------------|---|
| <b>Arm title</b> | NOR-204: GI.1/GII.4 (15/50/500/15) µg - MPL 15 µg, 2-Dose |
|------------------|---|

Arm description:

Eligible NOR-204 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide and 15 µg of MPL (Composition B), IM, on Day 1 and Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|  |                          |
|--|--------------------------|
| Arm type                               | Experimental             |
| Investigational medicinal product name | Hepatitis A Vaccine      |
| Investigational medicinal product code |                          |
| Other name                             | Havrix                   |
| Pharmaceutical forms                   | Suspension for injection |
| Routes of administration               | Intramuscular use        |

Dosage and administration details:

Hepatitis A vaccine, intramuscular injection (IM)

|                  |  |
|------------------|--|
| <b>Arm title</b> | NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose |
|------------------|--|

Arm description:

Eligible NOR-204 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 50 µg of GII.4 bivalent VLP) adjuvanted with 500 µg aluminium hydroxide (Composition A) IM, on Day 1 and Day

29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|  |                          |
|--|--------------------------|
| Arm type                               | Experimental             |
| Investigational medicinal product name | Hepatitis A Vaccine      |
| Investigational medicinal product code |                          |
| Other name                             | Havrix                   |
| Pharmaceutical forms                   | Suspension for injection |
| Routes of administration               | Intramuscular use        |

Dosage and administration details:

Hepatitis A vaccine, intramuscular injection (IM)

| <b>Number of subjects in period 1</b> | NOR-107:<br>GI.1/GII.4<br>(15/15/500) µg- | NOR-107: GI.1/GII.4<br>(15/50/500) µg-<br>MPL 50 µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(50/50/500) µg- |
|---------------------------------------|---|--|---|
| Started                               | 25  | 19   | 27  |
| Per Protocol Set (PPS)                | 25  | 19   | 27  |
| Completed                             | 21  | 19   | 26  |
| Not completed                         | 4   | 0  | 1   |
| Withdrawal of Consent                 | 1   | -  | -   |
| Adverse event, serious fatal          | -   | -  | -   |
| Reason, not Specified                 | 1   | -  | -   |
| Lost to follow-up                     | 2   | -  | 1   |

| <b>Number of subjects in period 1</b> | NOR-107:<br>GI.1/GII.4<br>(15/15/500) µg- | NOR-107: GI.1/GII.4<br>(15/50/500) µg-<br>MPL 15 µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(50/50/500) µg- |
|---------------------------------------|---|--|---|
| Started                               | 27  | 23   | 27  |
| Per Protocol Set (PPS)                | 26  | 23   | 27  |
| Completed                             | 25  | 23   | 26  |
| Not completed                         | 2   | 0  | 1   |
| Withdrawal of Consent                 | 1   | -  | -   |
| Adverse event, serious fatal          | -   | -  | -   |
| Reason, not Specified                 | -   | -  | -   |
| Lost to follow-up                     | 1   | -  | 1   |

| <b>Number of subjects in period 1</b> | NOR-107:<br>GI.1/GII.4<br>(15/15/500) µg,1- | NOR-107: GI.1/GII.4<br>(15/50/500) µg,1-<br>Dose | NOR-107:<br>GI.1/GII.4<br>(50/50/500) µg,1- |
|---------------------------------------|---|--|---|
| Started                               | 25  | 28   | 22  |
| Per Protocol Set (PPS)                | 25  | 28   | 22  |
| Completed                             | 24  | 27   | 22  |
| Not completed                         | 1   | 1  | 0   |
| Withdrawal of Consent                 | -   | -  | -   |
| Adverse event, serious fatal          | -   | -  | -   |
| Reason, not Specified                 | -   | -  | -   |
| Lost to follow-up                     | 1   | 1  | -   |

| Number of subjects in period 1 | NOR-107:<br>GI.1/GII.4<br>(50/150/500) µg,1- | NOR-107: GI.1/GII.4<br>(15/50/167) µg,1-<br>Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/500) µg,2- |
|--------------------------------|--|--|---|
| Started                        | 28   | 21   | 25  |
| Per Protocol Set (PPS)         | 28   | 19 <sup>[1]</sup>                                | 25  |
| Completed                      | 26   | 20   | 25  |
| Not completed                  | 2  | 1  | 0   |
| Withdrawal of Consent          | 1  | -  | -   |
| Adverse event, serious fatal   | -  | -  | -   |
| Reason, not Specified          | -  | -  | -   |
| Lost to follow-up              | 1  | 1  | -   |

| Number of subjects in period 1 | NOR-107:<br>GI.1/GII.4<br>(50/150/500) µg,2- | NOR-107: GI.1/GII.4<br>(15/50/167) µg,2-<br>Dose | NOR-210:<br>GI.1/GII.4<br>(15/50/500) µg, 1- |
|--------------------------------|--|--|--|
| Started                        | 24   | 24   | 24   |
| Per Protocol Set (PPS)         | 24   | 24   | 24   |
| Completed                      | 21   | 24   | 20   |
| Not completed                  | 3  | 0  | 4  |
| Withdrawal of Consent          | 2  | -  | 1  |
| Adverse event, serious fatal   | -  | -  | -  |
| Reason, not Specified          | -  | -  | -  |
| Lost to follow-up              | 1  | -  | 3  |

| Number of subjects in period 1 | NOR-204:<br>GI.1/GII.4<br>(15/50/500) µg, 1- | NOR-204: GI.1/GII.4<br>(15/50/500) µg, 1-<br>Dose (Age: 60-94<br>Yrs) | NOR-204:<br>GI.1/GII.4<br>(15/50/500) µg, 1-<br>Dose (Age: 18-49 |
|--------------------------------|--|---|--|
|                                |  |   |  |
| Started                        | 29   | 39  | 14   |
| Per Protocol Set (PPS)         | 29   | 39  | 14   |
| Completed                      | 22   | 29  | 12   |
| Not completed                  | 7  | 10  | 2  |
| Withdrawal of Consent          | 5  | 3   | -  |
| Adverse event, serious fatal   | 1  | 3   | -  |
| Reason, not Specified          | -  | 2   | -  |
| Lost to follow-up              | 1  | 2   | 2  |

| Number of subjects in period 1 | NOR-204:<br>GI.1/GII.4<br>(15/50/500/15) µg -<br>MPL 15 µg, 2-Dose | NOR-204: GI.1/GII.4<br>(15/50/500) µg, 2-<br>Dose |
|--------------------------------|--|---|
|                                |  |   |
| Started                        | 35   | 42  |
| Per Protocol Set (PPS)         | 35   | 42  |
| Completed                      | 29   | 34  |
| Not completed                  | 6  | 8   |
| Withdrawal of Consent          | 2  | 5   |
| Adverse event, serious fatal   | 2  | -   |
| Reason, not Specified          | 1  | -   |

|                   |   |   |
|-------------------|---|---|
| Lost to follow-up | 1 | 3 |
|-------------------|---|---|

---

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Per Protocol Set (PPS) included all participants in the FAS who had no major or critical protocol violations that potentially confound the primary endpoint.

## Baseline characteristics

### Reporting groups

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-107: GI.1/GII.4 (15/15/500) µg- MPL 50 µg,1-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus virus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-107: GI.1/GII.4 (15/50/500) µg- MPL 50 µg,1-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-107: GI.1/GII.4 (50/50/500) µg- MPL 50 µg,1-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-107: GI.1/GII.4 (15/15/500) µg- MPL 15 µg,1-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-107: GI.1/GII.4 (15/50/500) µg- MPL 15 µg,1-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-107 participants who had received IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-107: GI.1/GII.4 (50/50/500) µg- MPL 15 µg,1-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-107 participants who received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-107: GI.1/GII.4 (15/15/500) µg,1-Dose |
|-----------------------|---|

Reporting group description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-107: GI.1/GII.4 (15/50/500) µg,1-Dose |
|-----------------------|---|

Reporting group description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-107: GI.1/GII.4 (50/50/500) µg,1-Dose |
|-----------------------|---|

Reporting group description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-107: GI.1/GII.4 (50/150/500) µg,1-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-107: GI.1/GII.4 (15/50/167) µg,1-Dose |
|-----------------------|---|

Reporting group description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-107: GI.1/GII.4 (15/50/500) µg,2-Dose |
|-----------------------|---|

Reporting group description:

Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-107: GI.1/GII.4 (50/150/500) µg,2-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-107: GI.1/GII.4 (15/50/167) µg,2-Dose |
|-----------------------|---|

Reporting group description:

Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-210 participants who had received Norovirus GI.1/GII.4 bivalent VLP vaccine NoV Vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP, adjuvanted with 500 µg aluminium hydroxide), IM injection, once on Day 1 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-204 participants who had received Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) [15 µg of GI.1 and 50 µg of GII.4 bivalent virus-like particle (VLP)] adjuvanted with 500 µg aluminium hydroxide and 15 µg of monophosphoryl lipid A (MPL) (Composition B), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs) |
|-----------------------|---|

Reporting group description:

Eligible NOR-204 participants of age 60-94 years who had received Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus (NoV) [15 µg of GI.1 and 50 µg of GII.4 bivalent virus-like particle (VLP)] adjuvanted with 500 µg aluminium hydroxide (Composition A), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs) |
|-----------------------|---|

Reporting group description:

Eligible NOR-204 participants of age 18-49 years who had received Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus (NoV) [15 µg of GI.1 and 50 µg of GII.4 bivalent virus-like particle (VLP)] adjuvanted with 500 µg aluminium hydroxide (Composition A), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-204: GI.1/GII.4 (15/50/500/15) µg - MPL 15 µg, 2-Dose |
|-----------------------|---|

Reporting group description:

Eligible NOR-204 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide and 15 µg of MPL (Composition B), IM, on Day 1 and Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-204 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 50 µg of

| Reporting group values             | NOR-107:<br>GI.1/GII.4<br>(15/15/500) µg- | NOR-107: GI.1/GII.4<br>(15/50/500) µg-<br>MPL 50 µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(50/50/500) µg- |
|------------------------------------|---|--|---|
| Number of subjects                 | 25  | 19   | 27  |
| Age Categorical<br>Units: Subjects |   |  |   |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| Age continuous<br>Units: years<br>arithmetic mean<br>standard deviation | 48.1<br>± 14.24 | 47.9<br>± 14.60 | 46.8<br>± 13.39 |
| Gender categorical<br>Units: Subjects                                   |                 |                 |                 |
| Female  | 16              | 13              | 19              |
| Male  | 9               | 6               | 8               |
| Ethnicity (NIH/OMB)<br>Units: Subjects                                  |                 |                 |                 |
| Hispanic or Latino  | 0               | 0               | 0               |
| Not Hispanic or Latino  | 0               | 0               | 0               |
| Unknown or Not Reported   | 25              | 19              | 27              |
| Race (NIH/OMB)<br>Units: Subjects                                       |                 |                 |                 |
| American Indian or Alaska Native  | 0               | 0               | 0               |
| Asian   | 0               | 0               | 0               |
| Native Hawaiian or Other Pacific Islander                               | 0               | 0               | 0               |
| Black or African American   | 0               | 0               | 0               |
| White   | 25              | 19              | 27              |
| More than one race  | 0               | 0               | 0               |
| Unknown or Not Reported   | 0               | 0               | 0               |

| Reporting group values             | NOR-107:<br>GI.1/GII.4<br>(15/15/500) µg- | NOR-107: GI.1/GII.4<br>(15/50/500) µg-<br>MPL 15 µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(50/50/500) µg- |
|------------------------------------|---|--|---|
| Number of subjects                 | 27  | 23   | 27  |
| Age Categorical<br>Units: Subjects |   |  |   |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| Age continuous<br>Units: years<br>arithmetic mean<br>standard deviation | 47.5<br>± 13.96 | 48.0<br>± 13.49 | 48.0<br>± 13.13 |
| Gender categorical<br>Units: Subjects                                   |                 |                 |                 |
| Female  | 20              | 14              | 21              |
| Male  | 7               | 9               | 6               |

|   |    |    |    |
|---|----|----|----|
| Ethnicity (NIH/OMB)                       |    |    |    |
| Units: Subjects                           |    |    |    |
| Hispanic or Latino                        | 0  | 0  | 0  |
| Not Hispanic or Latino                    | 0  | 0  | 0  |
| Unknown or Not Reported                   | 27 | 23 | 27 |
| Race (NIH/OMB)                            |    |    |    |
| Units: Subjects                           |    |    |    |
| American Indian or Alaska Native          | 0  | 0  | 0  |
| Asian                                     | 1  | 0  | 1  |
| Native Hawaiian or Other Pacific Islander | 0  | 0  | 0  |
| Black or African American                 | 0  | 0  | 0  |
| White                                     | 26 | 23 | 26 |
| More than one race                        | 0  | 0  | 0  |
| Unknown or Not Reported                   | 0  | 0  | 0  |

|                               |   |  |   |
|-------------------------------|---|--|---|
| <b>Reporting group values</b> | NOR-107:<br>GI.1/GII.4<br>(15/15/500) µg,1- | NOR-107: GI.1/GII.4<br>(15/50/500) µg,1-<br>Dose | NOR-107:<br>GI.1/GII.4<br>(50/50/500) µg,1- |
| Number of subjects            | 25  | 28   | 22  |
| Age Categorical               |   |  |   |
| Units: Subjects               |   |  |   |

|   |         |         |         |
|---|---------|---------|---------|
| Age continuous                            |         |         |         |
| Units: years                              |         |         |         |
| arithmetic mean                           | 45.4    | 46.8    | 45.5    |
| standard deviation                        | ± 13.63 | ± 13.59 | ± 13.23 |
| Gender categorical                        |         |         |         |
| Units: Subjects                           |         |         |         |
| Female                                    | 12      | 14      | 16      |
| Male                                      | 13      | 14      | 6       |
| Ethnicity (NIH/OMB)                       |         |         |         |
| Units: Subjects                           |         |         |         |
| Hispanic or Latino                        | 0       | 0       | 0       |
| Not Hispanic or Latino                    | 0       | 0       | 0       |
| Unknown or Not Reported                   | 25      | 28      | 22      |
| Race (NIH/OMB)                            |         |         |         |
| Units: Subjects                           |         |         |         |
| American Indian or Alaska Native          | 0       | 0       | 0       |
| Asian                                     | 0       | 0       | 0       |
| Native Hawaiian or Other Pacific Islander | 0       | 0       | 0       |
| Black or African American                 | 0       | 0       | 0       |
| White                                     | 25      | 28      | 22      |
| More than one race                        | 0       | 0       | 0       |
| Unknown or Not Reported                   | 0       | 0       | 0       |

|                               |  |  |   |
|-------------------------------|--|--|---|
| <b>Reporting group values</b> | NOR-107:<br>GI.1/GII.4<br>(50/150/500) µg,1- | NOR-107: GI.1/GII.4<br>(15/50/167) µg,1-<br>Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/500) µg,2- |
| Number of subjects            | 28   | 21   | 25  |



|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| Age Categorical<br>Units: Subjects                                      |                 |                 |                 |
| Age continuous<br>Units: years<br>arithmetic mean<br>standard deviation | 44.0<br>± 15.20 | 41.9<br>± 16.17 | 42.6<br>± 13.33 |
| Gender categorical<br>Units: Subjects                                   |                 |                 |                 |
| Female  | 21              | 12              | 15              |
| Male  | 7               | 9               | 10              |
| Ethnicity (NIH/OMB)<br>Units: Subjects                                  |                 |                 |                 |
| Hispanic or Latino  | 0               | 0               | 0               |
| Not Hispanic or Latino  | 0               | 0               | 0               |
| Unknown or Not Reported   | 28              | 21              | 25              |
| Race (NIH/OMB)<br>Units: Subjects                                       |                 |                 |                 |
| American Indian or Alaska Native  | 0               | 0               | 0               |
| Asian   | 1               | 0               | 0               |
| Native Hawaiian or Other Pacific Islander                               | 0               | 0               | 0               |
| Black or African American   | 0               | 0               | 0               |
| White   | 27              | 21              | 25              |
| More than one race  | 0               | 0               | 0               |
| Unknown or Not Reported   | 0               | 0               | 0               |

|                                    |  |  |  |
|------------------------------------|--|--|--|
| <b>Reporting group values</b>      | NOR-107:<br>GI.1/GII.4<br>(50/150/500) µg,2- | NOR-107: GI.1/GII.4<br>(15/50/167) µg,2-<br>Dose | NOR-210:<br>GI.1/GII.4<br>(15/50/500) µg, 1- |
| Number of subjects                 | 24   | 24   | 24   |
| Age Categorical<br>Units: Subjects |  |  |  |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| Age continuous<br>Units: years<br>arithmetic mean<br>standard deviation | 47.3<br>± 13.98 | 46.3<br>± 15.17 | 35.0<br>± 9.44 |
| Gender categorical<br>Units: Subjects                                   |                 |                 |                |
| Female  | 18              | 16              | 10             |
| Male  | 6               | 8               | 14             |
| Ethnicity (NIH/OMB)<br>Units: Subjects                                  |                 |                 |                |
| Hispanic or Latino  | 0               | 0               | 5              |
| Not Hispanic or Latino  | 0               | 0               | 19             |
| Unknown or Not Reported   | 24              | 24              | 0              |
| Race (NIH/OMB)<br>Units: Subjects                                       |                 |                 |                |
| American Indian or Alaska Native  | 0               | 0               | 0              |
| Asian   | 0               | 0               | 0              |

|   |    |    |    |
|---|----|----|----|
| Native Hawaiian or Other Pacific Islander | 0  | 0  | 0  |
| Black or African American                 | 0  | 0  | 7  |
| White                                     | 24 | 24 | 16 |
| More than one race                        | 0  | 0  | 1  |
| Unknown or Not Reported                   | 0  | 0  | 0  |

| <b>Reporting group values</b>      | NOR-204:<br>GI.1/GII.4<br>(15/50/500) µg, 1-<br>Dose | NOR-204: GI.1/GII.4<br>(15/50/500) µg, 1-<br>Dose (Age: 60-94<br>Yrs) | NOR-204:<br>GI.1/GII.4<br>(15/50/500) µg, 1-<br>Dose (Age: 18-49 |
|------------------------------------|--|---|--|
| Number of subjects                 | 29   | 39  | 14   |
| Age Categorical<br>Units: Subjects |  |   |  |

|   |                |                |                |
|---|----------------|----------------|----------------|
| Age continuous<br>Units: years<br>arithmetic mean<br>standard deviation | 73.6<br>± 8.50 | 77.2<br>± 9.48 | 35.6<br>± 7.27 |
| Gender categorical<br>Units: Subjects                                   |                |                |                |
| Female  | 20             | 19             | 7              |
| Male  | 9              | 20             | 7              |
| Ethnicity (NIH/OMB)<br>Units: Subjects                                  |                |                |                |
| Hispanic or Latino  | 1              | 2              | 1              |
| Not Hispanic or Latino  | 28             | 37             | 13             |
| Unknown or Not Reported   | 0              | 0              | 0              |
| Race (NIH/OMB)<br>Units: Subjects                                       |                |                |                |
| American Indian or Alaska Native  | 0              | 0              | 0              |
| Asian   | 0              | 1              | 0              |
| Native Hawaiian or Other Pacific Islander                               | 0              | 0              | 1              |
| Black or African American   | 1              | 0              | 1              |
| White   | 28             | 38             | 12             |
| More than one race  | 0              | 0              | 0              |
| Unknown or Not Reported   | 0              | 0              | 0              |

| <b>Reporting group values</b>      | NOR-204:<br>GI.1/GII.4<br>(15/50/500/15) µg -<br>MPL 15 µg, 2-Dose | NOR-204: GI.1/GII.4<br>(15/50/500) µg, 2-<br>Dose | Total |
|------------------------------------|--|---|-------|
| Number of subjects                 | 35   | 42  | 528   |
| Age Categorical<br>Units: Subjects |  |   |       |

|   |                |                |     |
|---|----------------|----------------|-----|
| Age continuous<br>Units: years<br>arithmetic mean<br>standard deviation | 76.9<br>± 9.94 | 76.1<br>± 8.41 | -   |
| Gender categorical<br>Units: Subjects                                   |                |                |     |
| Female  | 18             | 23             | 324 |

|      |    |    |     |
|------|----|----|-----|
| Male | 17 | 19 | 204 |
|------|----|----|-----|

|   |    |    |     |
|---|----|----|-----|
| Ethnicity (NIH/OMB)                       |    |    |     |
| Units: Subjects                           |    |    |     |
| Hispanic or Latino                        | 3  | 3  | 15  |
| Not Hispanic or Latino                    | 32 | 39 | 168 |
| Unknown or Not Reported                   | 0  | 0  | 345 |
| Race (NIH/OMB)                            |    |    |     |
| Units: Subjects                           |    |    |     |
| American Indian or Alaska Native          | 0  | 0  | 0   |
| Asian                                     | 0  | 0  | 4   |
| Native Hawaiian or Other Pacific Islander | 0  | 0  | 1   |
| Black or African American                 | 0  | 3  | 12  |
| White                                     | 35 | 39 | 510 |
| More than one race                        | 0  | 0  | 1   |
| Unknown or Not Reported                   | 0  | 0  | 0   |

## End points

### End points reporting groups

|  |  |
|--|--|
| Reporting group title  | NOR-107: GI.1/GII.4 (15/15/500) µg- MPL 50 µg,1-Dose |
| Reporting group description:<br>Eligible NOR-107 participants who had received Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus virus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study. |  |
| Reporting group title  | NOR-107: GI.1/GII.4 (15/50/500) µg- MPL 50 µg,1-Dose |
| Reporting group description:<br>Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.  |  |
| Reporting group title  | NOR-107: GI.1/GII.4 (50/50/500) µg- MPL 50 µg,1-Dose |
| Reporting group description:<br>Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.  |  |
| Reporting group title  | NOR-107: GI.1/GII.4 (15/15/500) µg- MPL 15 µg,1-Dose |
| Reporting group description:<br>Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.  |  |
| Reporting group title  | NOR-107: GI.1/GII.4 (15/50/500) µg- MPL 15 µg,1-Dose |
| Reporting group description:<br>Eligible NOR-107 participants who had received IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.   |  |
| Reporting group title  | NOR-107: GI.1/GII.4 (50/50/500) µg- MPL 15 µg,1-Dose |
| Reporting group description:<br>Eligible NOR-107 participants who received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.  |  |
| Reporting group title  | NOR-107: GI.1/GII.4 (15/15/500) µg,1-Dose            |
| Reporting group description:<br>Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.  |  |
| Reporting group title  | NOR-107: GI.1/GII.4 (15/50/500) µg,1-Dose            |
| Reporting group description:<br>Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.  |  |
| Reporting group title  | NOR-107: GI.1/GII.4 (50/50/500) µg,1-Dose            |
| Reporting group description:<br>Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.  |  |

Reporting group description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-107: GI.1/GII.4 (15/50/167) µg,1-Dose |
|-----------------------|---|

Reporting group description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-107: GI.1/GII.4 (15/50/500) µg,2-Dose |
|-----------------------|---|

Reporting group description:

Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-107: GI.1/GII.4 (50/150/500) µg,2-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-107: GI.1/GII.4 (15/50/167) µg,2-Dose |
|-----------------------|---|

Reporting group description:

Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-210 participants who had received Norovirus GI.1/GII.4 bivalent VLP vaccine NoV Vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP, adjuvanted with 500 µg aluminium hydroxide), IM injection, once on Day 1 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-204 participants who had received Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) [15 µg of GI.1 and 50 µg of GII.4 bivalent virus-like particle (VLP)] adjuvanted with 500 µg aluminium hydroxide and 15 µg of monophosphoryl lipid A (MPL) (Composition B), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs) |
|-----------------------|---|

Reporting group description:

Eligible NOR-204 participants of age 60-94 years who had received Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus (NoV) [15 µg of GI.1 and 50 µg of GII.4 bivalent virus-like particle (VLP)] adjuvanted with 500 µg aluminium hydroxide (Composition A), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs) |
|-----------------------|---|

Reporting group description:

Eligible NOR-204 participants of age 18-49 years who had received Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus (NoV) [15 µg of GI.1 and 50 µg of GII.4 bivalent virus-like particle (VLP)] adjuvanted with 500 µg aluminium hydroxide (Composition A), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-204: GI.1/GII.4 (15/50/500/15) µg - MPL 15 µg, 2-Dose |
|-----------------------|---|

Reporting group description:

Eligible NOR-204 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide and 15 µg of MPL (Composition B), IM, on Day 1 and Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-204 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 50 µg of

**Primary: Geometric Mean Blocking Titers 50 percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as measured by Histo-Blood Group Antigen (HBGA) blocking assay**

|                 |  |
|-----------------|--|
| End point title | Geometric Mean Blocking Titers 50 percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies as measured by Histo-Blood Group Antigen (HBGA) blocking assay <sup>[1]</sup> |
|-----------------|--|

End point description:

GMBT50 of anti-norovirus GI. VLP antibody titers as measured by HBGA blocking assay. Data reported for up to Year 5 was collected at Baseline, Days 28, 29, 36, 56, 57, 208, 211 Year 2, 3, 4, and 5. PPS=all participants in the FAS who had no major or critical protocol violations. n=number of participants with data available for analysis at specific timepoints. Baseline (n=25, 19, 27, 26, 23, 27, 25, 28, 22, 28, 19, 25, 24, 24, 24, 29, 39, 14, 35, 42) D28 (n=25, 19, 26, 26, 23, 27, 25, 28, 21, 28, 19, 25, 24, 24) D29 (n=24, 29, 39, 14, 35, 42) D36 (n=29, 39, 14, 35, 42) D56 (n=25, 19, 27, 26, 23, 27, 25, 28, 22, 28, 19, 25, 24, 24) D57 (n=29, 39, 14, 35, 42) D208 (n=25, 19, 27, 26, 23, 27, 25, 28, 22, 28, 19, 25, 24, 24) D211 (n=29, 39, 14, 35, 42) Y2 (n=24, 26, 37, 10, 32, 34) Y3 (n=24, 19, 27, 26, 23, 26, 25, 28, 22, 27, 19, 25, 24, 24, 21, 24, 35, 13, 29, 37) Y4 (n=23, 19, 26, 26, 23, 26, 23, 28, 22, 28, 19, 25, 23, 24, 20, 18, 22, 11, 20, 27) Y5 (n=21, 19, 26, 24, 23, 26, 24, 27, 22, 25, 19, 24, 21, 24, 19, 8, 13, 10, 10, 16). 999, 9999, 99999=No participants were analyzed at specific timepoints in NOR-107, NOR-210, NOR-204 study respectively.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to 5 years post-primary vaccination

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was performed for this primary endpoint.

| End point values                         | NOR-107:<br>GI.1/GII.4<br>(15/15/500)<br>µg- MPL 50<br>µg, 1-Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/500)<br>µg- MPL 50<br>µg, 1-Dose | NOR-107:<br>GI.1/GII.4<br>(50/50/500)<br>µg- MPL 50<br>µg, 1-Dose | NOR-107:<br>GI.1/GII.4<br>(15/15/500)<br>µg- MPL 15<br>µg, 1-Dose |
|--|---|---|---|---|
| Subject group type                       | Reporting group   | Reporting group   | Reporting group   | Reporting group   |
| Number of subjects analysed              | 25  | 19  | 27  | 26  |
| Units: titer                             |   |   |   |   |
| geometric mean (confidence interval 95%) |   |   |   |   |
| Baseline                                 | 27.4 (17.5 to 42.9)   | 18.3 (13.4 to 24.9)   | 26.3 (17.4 to 39.6)   | 24.6 (15.5 to 38.9)   |
| Day 28                                   | 27.7 (18.2 to 42.2)   | 18.1 (13.2 to 24.8)   | 23.8 (16.4 to 34.5)   | 24.0 (15.4 to 37.3)   |
| Day 29                                   | 999 (-999 to 999)   | 999 (-999 to 999)   | 999 (-999 to 999)   | 999 (-999 to 999)   |
| Day 36                                   | 999 (-999 to 999)   | 999 (-999 to 999)   | 999 (-999 to 999)   | 999 (-999 to 999)   |
| Day 56                                   | 309.7 (168.7 to 568.4)  | 256.9 (136.3 to 484.0)  | 380.9 (227.0 to 639.2)  | 255.4 (132.3 to 493.1)  |
| Day 57                                   | 999 (-999 to 999)   | 999 (-999 to 999)   | 999 (-999 to 999)   | 999 (-999 to 999)   |
| Day 208                                  | 143.5 (84.7 to 243.2)   | 109.1 (62.9 to 189.1)   | 154.8 (95.7 to 250.4)   | 125.6 (74.9 to 210.8)   |
| Day 211                                  | 999 (-999 to 999)   | 999 (-999 to 999)   | 999 (-999 to 999)   | 999 (-999 to 999)   |
| Year 2                                   | 999 (-999 to 999)   | 999 (-999 to 999)   | 999 (-999 to 999)   | 999 (-999 to 999)   |

|        |                      |                     |                      |                      |
|--------|----------------------|---------------------|----------------------|----------------------|
| Year 3 | 79.6 (48.9 to 129.7) | 53.7 (32.8 to 88.0) | 77.2 (49.1 to 121.3) | 72.4 (44.0 to 119.1) |
| Year 4 | 70.5 (38.0 to 130.9) | 47.5 (27.3 to 82.7) | 68.6 (38.6 to 122.0) | 54.0 (30.4 to 96.1)  |
| Year 5 | 71.0 (37.8 to 133.6) | 42.5 (25.0 to 72.4) | 80.5 (45.0 to 144.0) | 54.4 (30.8 to 96.2)  |

| <b>End point values</b>                  | NOR-107:<br>GI.1/GII.4<br>(15/50/500)<br>µg- MPL 15<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(50/50/500)<br>µg- MPL 15<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(15/15/500)<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/500)<br>µg,1-Dose |
|--|--|--|--|--|
| Subject group type                       | Reporting group  | Reporting group  | Reporting group                                    | Reporting group                                    |
| Number of subjects analysed              | 23   | 27   | 25   | 28   |
| Units: titer                             |  |  |  |  |
| geometric mean (confidence interval 95%) |  |  |  |  |
| Baseline                                 | 19.0 (15.5 to 23.2)  | 23.9 (17.2 to 33.2)  | 35.1 (21.7 to 56.9)                                | 24.3 (16.5 to 35.8)                                |
| Day 28                                   | 17.4 (14.5 to 20.9)  | 21.9 (16.1 to 29.9)  | 29.9 (20.2 to 44.2)                                | 24.9 (17.2 to 36.1)                                |
| Day 29                                   | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)                                  | 999 (-999 to 999)                                  |
| Day 36                                   | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)                                  | 999 (-999 to 999)                                  |
| Day 56                                   | 252.9 (136.7 to 468.1)   | 329.2 (192.9 to 561.9)   | 369.5 (221.0 to 617.8)                             | 350.4 (194.5 to 631.2)                             |
| Day 57                                   | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)                                  | 999 (-999 to 999)                                  |
| Day 208                                  | 86.4 (50.5 to 148.1)   | 137.9 (93.7 to 202.8)  | 168.9 (109.1 to 261.5)                             | 175.4 (111.6 to 275.6)                             |
| Day 211                                  | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)                                  | 999 (-999 to 999)                                  |
| Year 2                                   | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)                                  | 999 (-999 to 999)                                  |
| Year 3                                   | 51.5 (33.1 to 80.1)  | 55.5 (35.4 to 86.8)  | 98.0 (65.1 to 147.5)                               | 90.2 (60.1 to 135.5)                               |
| Year 4                                   | 54.8 (30.2 to 99.7)  | 49.3 (31.5 to 77.2)  | 84.9 (49.6 to 145.2)                               | 67.3 (41.1 to 109.9)                               |
| Year 5                                   | 50.5 (28.7 to 89.1)  | 54.5 (31.0 to 96.0)  | 77.2 (48.4 to 123.1)                               | 82.2 (49.0 to 137.7)                               |

| <b>End point values</b>                  | NOR-107:<br>GI.1/GII.4<br>(50/50/500)<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(50/150/500)<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/167)<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/500)<br>µg,2-Dose |
|--|--|---|--|--|
| Subject group type                       | Reporting group                                    | Reporting group                                     | Reporting group                                    | Reporting group                                    |
| Number of subjects analysed              | 22   | 28  | 19   | 25   |
| Units: titer                             |  |   |  |  |
| geometric mean (confidence interval 95%) |  |   |  |  |
| Baseline                                 | 26.1 (16.8 to 40.5)                                | 23.9 (17.5 to 32.7)                                 | 33.4 (19.4 to 57.6)                                | 23.1 (16.4 to 32.6)                                |
| Day 28                                   | 27.3 (17.2 to 43.4)                                | 25.8 (18.3 to 36.3)                                 | 34.9 (20.8 to 58.5)                                | 382.6 (200.9 to 728.5)                             |

|         |                         |                        |                        |                        |
|---------|-------------------------|------------------------|------------------------|------------------------|
| Day 29  | 999 (-999 to 999)       | 999 (-999 to 999)      | 999 (-999 to 999)      | 999 (-999 to 999)      |
| Day 36  | 999 (-999 to 999)       | 999 (-999 to 999)      | 999 (-999 to 999)      | 999 (-999 to 999)      |
| Day 56  | 527.0 (264.1 to 1051.5) | 274.3 (171.6 to 438.4) | 315.8 (154.5 to 645.2) | 435.9 (288.8 to 658.0) |
| Day 57  | 999 (-999 to 999)       | 999 (-999 to 999)      | 999 (-999 to 999)      | 999 (-999 to 999)      |
| Day 208 | 214.1 (120.7 to 379.6)  | 125.3 (83.7 to 187.6)  | 115.3 (61.5 to 216.0)  | 208.7 (134.0 to 324.9) |
| Day 211 | 999 (-999 to 999)       | 999 (-999 to 999)      | 999 (-999 to 999)      | 999 (-999 to 999)      |
| Year 2  | 999 (-999 to 999)       | 999 (-999 to 999)      | 999 (-999 to 999)      | 999 (-999 to 999)      |
| Year 3  | 102.2 (56.4 to 185.0)   | 61.8 (40.5 to 94.3)    | 67.2 (34.5 to 131.1)   | 90.5 (55.4 to 147.6)   |
| Year 4  | 78.2 (41.9 to 146.1)    | 45.5 (30.0 to 68.9)    | 61.2 (30.9 to 121.0)   | 85.8 (57.9 to 127.0)   |
| Year 5  | 80.9 (43.3 to 151.1)    | 54.1 (32.6 to 89.7)    | 62.0 (32.5 to 118.5)   | 82.1 (50.9 to 132.4)   |

| <b>End point values</b>                  | NOR-107:<br>GI.1/GII.4<br>(50/150/500)<br>µg,2-Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/167)<br>µg,2-Dose | NOR-210:<br>GI.1/GII.4<br>(15/50/500)<br>µg, 1-Dose | NOR-204:<br>GI.1/GII.4<br>(15/50/500)<br>µg, 1-Dose |
|--|---|--|---|---|
| Subject group type                       | Reporting group                                     | Reporting group                                    | Reporting group                                     | Reporting group                                     |
| Number of subjects analysed              | 24  | 24   | 24  | 29  |
| Units: titer                             |   |  |   |   |
| geometric mean (confidence interval 95%) |   |  |   |   |
| Baseline                                 | 22.9 (15.9 to 32.9)                                 | 21.3 (15.4 to 29.3)                                | 19.0 (14.1 to 25.6)                                 | 20.8 (16.4 to 26.3)                                 |
| Day 28                                   | 338.0 (196.7 to 580.7)                              | 449.4 (270.5 to 746.5)                             | 9999 (-9999 to 9999)                                | 99999 (-99999 to 99999)                             |
| Day 29                                   | 999 (-999 to 999)                                   | 999 (-999 to 999)                                  | 212.5 (129.9 to 347.5)                              | 21.3 (16.9 to 26.9)                                 |
| Day 36                                   | 999 (-999 to 999)                                   | 999 (-999 to 999)                                  | 9999 (-9999 to 9999)                                | 263.3 (143.3 to 483.9)                              |
| Day 56                                   | 427.6 (300.0 to 609.6)                              | 377.4 (251.6 to 566.0)                             | 9999 (-9999 to 9999)                                | 99999 (-99999 to 99999)                             |
| Day 57                                   | 999 (-999 to 999)                                   | 999 (-999 to 999)                                  | 9999 (-9999 to 9999)                                | 228.9 (136.4 to 384.1)                              |
| Day 208                                  | 201.5 (141.3 to 287.4)                              | 185.6 (126.9 to 271.6)                             | 9999 (-9999 to 9999)                                | 99999 (-99999 to 99999)                             |
| Day 211                                  | 999 (-999 to 999)                                   | 999 (-999 to 999)                                  | 9999 (-9999 to 9999)                                | 115.9 (72.1 to 186.4)                               |
| Year 2                                   | 999 (-999 to 999)                                   | 999 (-999 to 999)                                  | 48.8 (31.2 to 76.4)                                 | 46.3 (30.7 to 69.8)                                 |
| Year 3                                   | 84.9 (53.1 to 135.6)                                | 85.7 (55.9 to 131.4)                               | 48.2 (29.0 to 80.1)                                 | 48.8 (30.3 to 78.8)                                 |
| Year 4                                   | 65.1 (39.0 to 108.8)                                | 67.2 (42.9 to 105.2)                               | 63.8 (35.0 to 116.2)                                | 28.6 (17.3 to 47.2)                                 |
| Year 5                                   | 69.1 (42.3 to 112.6)                                | 74.9 (49.1 to 114.2)                               | 52.8 (28.6 to 97.4)                                 | 34.7 (15.8 to 76.1)                                 |



| End point values                            | NOR-204:<br>GI.1/GII.4<br>(15/50/500)<br>µg, 1-Dose<br>(Age: 60-94<br>Yrs) | NOR-204:<br>GI.1/GII.4<br>(15/50/500)<br>µg, 1-Dose<br>(Age: 18-49<br>Yrs) | NOR-204:<br>GI.1/GII.4<br>(15/50/500/15<br>) µg - MPL 15<br>µg, 2-Dose | NOR-204:<br>GI.1/GII.4<br>(15/50/500)<br>µg, 2-Dose |
|---|--|--|--|---|
| Subject group type                          | Reporting group  | Reporting group  | Reporting group  | Reporting group                                     |
| Number of subjects analysed                 | 39   | 14   | 35   | 42  |
| Units: titer                                |  |  |  |   |
| geometric mean (confidence interval<br>95%) |  |  |  |   |
| Baseline                                    | 28.9 (20.7 to<br>40.5)   | 18.7 (13.0 to<br>26.9)   | 23.9 (18.5 to<br>30.8)   | 26.4 (19.4 to<br>36.1)                              |
| Day 28                                      | 99999 (-99999<br>to 99999)   | 99999 (-99999<br>to 99999)   | 99999 (-99999<br>to 99999)   | 99999 (-99999<br>to 99999)                          |
| Day 29                                      | 28.7 (20.6 to<br>40.0)   | 19.9 (13.5 to<br>29.2)   | 342.5 (206.3<br>to 568.5)  | 329.2 (213.3<br>to 508.2)                           |
| Day 36                                      | 213.4 (117.2<br>to 388.5)  | 155.3 (51.5 to<br>468.2)   | 406.4 (274.6<br>to 601.4)  | 307.2 (206.1<br>to 458.0)                           |
| Day 56                                      | 99999 (-99999<br>to 99999)   | 99999 (-99999<br>to 99999)   | 99999 (-99999<br>to 99999)   | 99999 (-99999<br>to 99999)                          |
| Day 57                                      | 223.0 (133.9<br>to 371.5)  | 105.1 (40.9 to<br>270.5)   | 362.5 (255.9<br>to 513.5)  | 304.3 (215.6<br>to 429.7)                           |
| Day 208                                     | 99999 (-99999<br>to 99999)   | 99999 (-99999<br>to 99999)   | 99999 (-99999<br>to 99999)   | 99999 (-99999<br>to 99999)                          |
| Day 211                                     | 96.5 (62.6 to<br>148.7)  | 43.4 (20.1 to<br>93.9)   | 132.9 (89.2 to<br>198.0)   | 126.6 (85.6 to<br>187.2)                            |
| Year 2                                      | 63.6 (39.6 to<br>102.1)  | 38.9 (16.7 to<br>90.6)   | 58.9 (39.8 to<br>87.2)   | 83.4 (58.2 to<br>119.3)                             |
| Year 3                                      | 60.7 (37.2 to<br>98.9)   | 34.0 (16.6 to<br>69.9)   | 72.5 (47.3 to<br>111.2)  | 76.1 (51.0 to<br>113.6)                             |
| Year 4                                      | 45.9 (25.0 to<br>84.3)   | 28.3 (14.2 to<br>56.2)   | 76.1 (45.6 to<br>127.2)  | 57.1 (34.5 to<br>94.3)                              |
| Year 5                                      | 41.9 (21.8 to<br>80.3)   | 31.9 (14.6 to<br>69.6)   | 59.8 (29.0 to<br>123.2)  | 65.5 (37.9 to<br>113.1)                             |

## Statistical analyses

No statistical analyses for this end point

### Primary: Geometric mean blocking titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as measured by HBGA blocking assay

|   |   |
|---|---|
| End point title   | Geometric mean blocking titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies as measured by HBGA blocking assay <sup>[2]</sup> |
| End point description:  |   |
| <p>GMBT50 of anti-norovirus GII. VLP antibody titers as measured by HBGA blocking assay. Data reported for up to Year 5 was collected at Baseline, Days 28, 29, 36, 56, 57, 208, 211 Year 2, 3, 4, and 5. PPS=all participants in FAS who had no major or critical protocol violations. n=number of participants with data available for analysis at specific timepoints. Baseline (n=25, 19, 27, 26, 23, 27, 25, 28, 22, 28, 19, 25, 24, 24, 29, 39, 14, 35, 42) D28 (n=25, 19, 26, 26, 23, 27, 25, 28, 21, 28, 19, 25, 24, 24) D29 (n=24, 29, 39, 14, 35, 42) D36 (n=29, 39, 14, 35, 42) D56 (n=25, 19, 27, 26, 23, 27, 25, 28, 22, 28, 19, 25, 24, 24) D57 (n=29, 39, 14, 35, 42) D208 (n=25, 19, 27, 26, 23, 27, 25, 28, 22, 28, 19, 25, 24, 24) D211 (n=29, 39, 14, 35, 42) Y2 (n=24, 26, 37, 10, 32, 35) Y3 (n=24, 19, 27, 26, 23, 27, 25, 28, 22, 27, 19, 25, 24, 24, 21, 24, 35, 13, 29, 37) Y4 (n=23, 19, 26, 26, 23, 26, 23, 28, 22, 28, 19, 25, 23, 24, 20, 18, 22, 11, 20, 27) Y5 (n=21, 19, 26, 24, 23, 26, 24, 27, 22, 25, 19, 24, 21, 24, 19, 8, 14, 10, 10, 17). 999, 9999, 99999=No participants were analyzed at specific timepoints in NOR-107, NOR-210, NOR-204 respectively.</p> |   |
| End point type  | Primary   |

End point timeframe:

Up to 5 years post-primary vaccination

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was performed for this primary endpoint.

| End point values                         | NOR-107:<br>GI.1/GII.4<br>(15/15/500)<br>µg- MPL 50<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/500)<br>µg- MPL 50<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(50/50/500)<br>µg- MPL 50<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(15/15/500)<br>µg- MPL 15<br>µg,1-Dose |
|--|--|--|--|--|
| Subject group type                       | Reporting group  | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 25   | 19   | 27   | 26   |
| Units: titer                             |  |  |  |  |
| geometric mean (confidence interval 95%) |  |  |  |  |
| Baseline                                 | 74.8 (38.1 to 147.0)   | 77.4 (41.9 to 142.8)   | 116.8 (65.9 to 207.2)  | 72.1 (41.6 to 125.1)   |
| Day 28                                   | 80.7 (42.3 to 153.9)   | 67.2 (35.2 to 128.0)   | 128.0 (73.3 to 223.7)  | 71.3 (42.2 to 120.7)   |
| Day 29                                   | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  |
| Day 36                                   | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  |
| Day 56                                   | 367.9 (214.8 to 630.3)   | 755.9 (425.6 to 1342.6)  | 425.1 (298.8 to 604.8)   | 277.9 (178.2 to 433.4)   |
| Day 57                                   | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  |
| Day 208                                  | 216.4 (132.8 to 352.6)   | 290.1 (182.7 to 460.7)   | 231.4 (152.0 to 352.4)   | 176.2 (116.1 to 267.4)   |
| Day 211                                  | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  |
| Year 2                                   | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  |
| Year 3                                   | 122.7 (65.7 to 229.2)  | 177.1 (96.8 to 323.9)  | 117.9 (69.6 to 199.7)  | 104.0 (60.2 to 179.6)  |
| Year 4                                   | 85.7 (46.7 to 157.1)   | 122.8 (67.4 to 223.6)  | 90.8 (54.4 to 151.3)   | 79.5 (48.3 to 130.8)   |
| Year 5                                   | 101.1 (52.5 to 194.6)  | 138.3 (80.8 to 236.9)  | 124.4 (78.5 to 197.0)  | 91.2 (51.2 to 162.3)   |

| End point values                         | NOR-107:<br>GI.1/GII.4<br>(15/50/500)<br>µg- MPL 15<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(50/50/500)<br>µg- MPL 15<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(15/15/500)<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/500)<br>µg,1-Dose |
|--|--|--|--|--|
| Subject group type                       | Reporting group  | Reporting group  | Reporting group                                    | Reporting group                                    |
| Number of subjects analysed              | 23   | 27   | 25   | 28   |
| Units: titer                             |  |  |  |  |
| geometric mean (confidence interval 95%) |  |  |  |  |
| Baseline                                 | 54.6 (30.7 to 97.3)  | 104.2 (60.4 to 179.8)  | 77.5 (42.5 to 141.6)                               | 86.3 (47.9 to 155.3)                               |
| Day 28                                   | 64.9 (36.6 to 115.3)   | 101.3 (57.1 to 179.6)  | 69.7 (40.2 to 120.9)                               | 95.2 (49.6 to 182.6)                               |

|         |                        |                        |                        |                         |
|---------|------------------------|------------------------|------------------------|-------------------------|
| Day 29  | 999 (-999 to 999)      | 999 (-999 to 999)      | 999 (-999 to 999)      | 999 (-999 to 999)       |
| Day 36  | 999 (-999 to 999)      | 999 (-999 to 999)      | 999 (-999 to 999)      | 999 (-999 to 999)       |
| Day 56  | 584.7 (367.5 to 930.1) | 593.4 (436.2 to 807.2) | 201.9 (110.6 to 368.4) | 810.0 (507.4 to 1293.2) |
| Day 57  | 999 (-999 to 999)      | 999 (-999 to 999)      | 999 (-999 to 999)      | 999 (-999 to 999)       |
| Day 208 | 215.9 (132.1 to 353.1) | 247.4 (166.6 to 367.3) | 150.4 (87.4 to 258.6)  | 333.2 (217.9 to 509.4)  |
| Day 211 | 999 (-999 to 999)      | 999 (-999 to 999)      | 999 (-999 to 999)      | 999 (-999 to 999)       |
| Year 2  | 999 (-999 to 999)      | 999 (-999 to 999)      | 999 (-999 to 999)      | 999 (-999 to 999)       |
| Year 3  | 80.5 (45.4 to 142.9)   | 125.9 (74.7 to 212.3)  | 121.2 (71.1 to 206.7)  | 164.1 (97.7 to 275.5)   |
| Year 4  | 61.7 (35.7 to 106.5)   | 106.7 (64.7 to 176.1)  | 108.6 (62.0 to 190.3)  | 131.2 (81.9 to 210.2)   |
| Year 5  | 71.3 (40.0 to 126.9)   | 103.2 (60.6 to 175.8)  | 94.3 (54.4 to 163.2)   | 144.9 (82.9 to 253.1)   |

| <b>End point values</b>                  | NOR-107:<br>GI.1/GII.4<br>(50/50/500)<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(50/150/500)<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/167)<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/500)<br>µg,2-Dose |
|--|--|---|--|--|
| Subject group type                       | Reporting group                                    | Reporting group                                     | Reporting group                                    | Reporting group                                    |
| Number of subjects analysed              | 22   | 28  | 19   | 25   |
| Units: titer                             |  |   |  |  |
| geometric mean (confidence interval 95%) |  |   |  |  |
| Baseline                                 | 97.1 (55.8 to 169.0)                               | 106.1 (66.7 to 168.8)                               | 124.3 (69.0 to 223.9)                              | 65.8 (39.6 to 109.1)                               |
| Day 28                                   | 84.1 (46.7 to 151.3)                               | 129.9 (83.4 to 202.4)                               | 112.4 (63.0 to 200.5)                              | 607.7 (379.2 to 974.0)                             |
| Day 29                                   | 999 (-999 to 999)                                  | 999 (-999 to 999)                                   | 999 (-999 to 999)                                  | 999 (-999 to 999)                                  |
| Day 36                                   | 999 (-999 to 999)                                  | 999 (-999 to 999)                                   | 999 (-999 to 999)                                  | 999 (-999 to 999)                                  |
| Day 56                                   | 328.5 (173.8 to 620.8)                             | 886.3 (562.3 to 1397.0)                             | 746.6 (456.8 to 1220.3)                            | 458.4 (290.9 to 722.3)                             |
| Day 57                                   | 999 (-999 to 999)                                  | 999 (-999 to 999)                                   | 999 (-999 to 999)                                  | 999 (-999 to 999)                                  |
| Day 208                                  | 173.0 (94.8 to 315.8)                              | 352.9 (242.4 to 513.8)                              | 274.9 (151.4 to 499.2)                             | 277.2 (186.5 to 412.0)                             |
| Day 211                                  | 999 (-999 to 999)                                  | 999 (-999 to 999)                                   | 999 (-999 to 999)                                  | 999 (-999 to 999)                                  |
| Year 2                                   | 999 (-999 to 999)                                  | 999 (-999 to 999)                                   | 999 (-999 to 999)                                  | 999 (-999 to 999)                                  |
| Year 3                                   | 125.3 (67.9 to 230.9)                              | 167.0 (111.3 to 250.4)                              | 142.2 (76.9 to 263.1)                              | 149.2 (83.1 to 267.9)                              |
| Year 4                                   | 101.9 (60.1 to 172.7)                              | 113.9 (73.3 to 177.1)                               | 130.1 (70.0 to 241.9)                              | 98.1 (55.0 to 175.1)                               |
| Year 5                                   | 105.1 (57.8 to 191.1)                              | 147.2 (92.4 to 234.4)                               | 118.0 (66.8 to 208.6)                              | 118.3 (71.4 to 195.8)                              |

| End point values                         | NOR-107:<br>GI.1/GII.4<br>(50/150/500)<br>µg, 2-Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/167)<br>µg, 2-Dose | NOR-210:<br>GI.1/GII.4<br>(15/50/500)<br>µg, 1-Dose | NOR-204:<br>GI.1/GII.4<br>(15/50/500)<br>µg, 1-Dose |
|--|--|---|---|---|
| Subject group type                       | Reporting group                                      | Reporting group                                     | Reporting group                                     | Reporting group                                     |
| Number of subjects analysed              | 24   | 24  | 24  | 29  |
| Units: titer                             |  |   |   |   |
| geometric mean (confidence interval 95%) |  |   |   |   |
| Baseline                                 | 97.2 (53.8 to 175.9)                                 | 127.3 (70.2 to 231.0)                               | 42.7 (25.6 to 71.1)                                 | 140.5 (78.5 to 251.6)                               |
| Day 28                                   | 668.3 (397.3 to 1124.0)                              | 893.6 (578.4 to 1380.5)                             | 9999 (-9999 to 9999)                                | 99999 (-99999 to 99999)                             |
| Day 29                                   | 999 (-999 to 999)                                    | 999 (-999 to 999)                                   | 665.9 (408.2 to 1086.2)                             | 118.3 (66.7 to 210.0)                               |
| Day 36                                   | 999 (-999 to 999)                                    | 999 (-999 to 999)                                   | 9999 (-9999 to 9999)                                | 920.9 (521.8 to 1625.4)                             |
| Day 56                                   | 575.5 (358.1 to 924.8)                               | 594.2 (369.2 to 956.2)                              | 9999 (-9999 to 9999)                                | 99999 (-99999 to 99999)                             |
| Day 57                                   | 999 (-999 to 999)                                    | 999 (-999 to 999)                                   | 9999 (-9999 to 9999)                                | 1133.2 (682.7 to 1881.0)                            |
| Day 208                                  | 342.5 (233.2 to 503.1)                               | 308.7 (198.5 to 480.0)                              | 9999 (-9999 to 9999)                                | 99999 (-99999 to 99999)                             |
| Day 211                                  | 999 (-999 to 999)                                    | 999 (-999 to 999)                                   | 9999 (-9999 to 9999)                                | 417.6 (252.8 to 689.6)                              |
| Year 2                                   | 999 (-999 to 999)                                    | 999 (-999 to 999)                                   | 105.2 (58.7 to 188.3)                               | 223.2 (120.7 to 412.9)                              |
| Year 3                                   | 144.7 (83.1 to 251.7)                                | 173.8 (104.6 to 288.8)                              | 87.5 (43.9 to 174.5)                                | 172.0 (100.1 to 295.5)                              |
| Year 4                                   | 104.4 (58.4 to 186.5)                                | 120.3 (72.6 to 199.3)                               | 84.1 (44.2 to 160.3)                                | 116.0 (54.0 to 249.4)                               |
| Year 5                                   | 115.7 (57.7 to 232.0)                                | 132.0 (79.7 to 218.5)                               | 94.2 (49.1 to 180.7)                                | 123.4 (26.5 to 574.3)                               |

| End point values                         | NOR-204:<br>GI.1/GII.4<br>(15/50/500)<br>µg, 1-Dose<br>(Age: 60-94 Yrs) | NOR-204:<br>GI.1/GII.4<br>(15/50/500)<br>µg, 1-Dose<br>(Age: 18-49 Yrs) | NOR-204:<br>GI.1/GII.4<br>(15/50/500/15)<br>µg - MPL 15<br>µg, 2-Dose | NOR-204:<br>GI.1/GII.4<br>(15/50/500)<br>µg, 2-Dose |
|--|---|---|---|---|
| Subject group type                       | Reporting group   | Reporting group   | Reporting group   | Reporting group                                     |
| Number of subjects analysed              | 39  | 14  | 35  | 42  |
| Units: titer                             |   |   |   |   |
| geometric mean (confidence interval 95%) |   |   |   |   |
| Baseline                                 | 71.8 (45.7 to 113.0)  | 97.5 (40.3 to 235.8)  | 104.9 (64.2 to 171.5)   | 111.0 (72.0 to 171.1)                               |
| Day 28                                   | 99999 (-99999 to 99999)   | 99999 (-99999 to 99999)   | 99999 (-99999 to 99999)   | 99999 (-99999 to 99999)                             |
| Day 29                                   | 63.5 (41.0 to 98.4)   | 83.2 (34.3 to 201.9)  | 1134.4 (784.6 to 1640.1)  | 824.2 (493.4 to 1376.8)                             |
| Day 36                                   | 518.7 (273.0 to 985.2)  | 1037.4 (448.1 to 2401.9)  | 1016.2 (719.4 to 1435.4)  | 766.8 (483.1 to 1216.9)                             |
| Day 56                                   | 99999 (-99999 to 99999)   | 99999 (-99999 to 99999)   | 99999 (-99999 to 99999)   | 99999 (-99999 to 99999)                             |
| Day 57                                   | 471.8 (285.2 to 780.5)  | 663.8 (304.5 to 1447.1)   | 740.2 (549.0 to 998.0)  | 589.1 (359.7 to 964.6)                              |

|         |                         |                         |                         |                         |
|---------|-------------------------|-------------------------|-------------------------|-------------------------|
| Day 208 | 99999 (-99999 to 99999) | 99999 (-99999 to 99999) | 99999 (-99999 to 99999) | 99999 (-99999 to 99999) |
| Day 211 | 195.2 (120.2 to 316.8)  | 274.7 (135.3 to 557.8)  | 374.7 (262.6 to 534.6)  | 265.3 (157.4 to 447.2)  |
| Year 2  | 122.5 (74.8 to 200.5)   | 250.5 (80.8 to 776.7)   | 220.9 (137.2 to 355.7)  | 243.0 (149.6 to 394.7)  |
| Year 3  | 94.9 (59.4 to 151.3)    | 133.8 (56.2 to 318.9)   | 153.3 (100.1 to 234.8)  | 162.4 (102.5 to 257.3)  |
| Year 4  | 80.9 (42.1 to 155.4)    | 131.1 (57.6 to 298.6)   | 241.9 (140.2 to 417.5)  | 136.7 (75.7 to 246.9)   |
| Year 5  | 66.8 (32.2 to 138.6)    | 107.4 (43.5 to 265.1)   | 202.2 (110.2 to 370.9)  | 187.3 (105.6 to 332.4)  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as measured by Total Immunoglobulin (pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA)

|                 |  |
|-----------------|--|
| End point title | Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies as measured by Total Immunoglobulin (pan-Ig) Enzyme-linked Immunosorbent Assay (ELISA) |
|-----------------|--|

End point description:

GMT of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA. Data reported for up to Year 5 was collected at Baseline, Days 28, 29, 36, 56, 57, 208, 211 Year 2, 3, 4, and 5. PPS=all participants in FAS who had no major or critical protocol violations. n=number of participants with data available for analysis at specific timepoints. Baseline

(n=25, 19, 27, 26, 23, 27, 25, 28, 22, 28, 19, 25, 24, 24, 24, 29, 39, 14, 35, 42) D28

(n=25, 19, 26, 26, 23, 27, 25, 28, 21, 28, 19, 25, 24, 24)

D29 (n=24, 29, 39, 14, 35, 42) D36 (n=29, 39, 14, 35, 42) D56

(n=25, 19, 27, 26, 23, 27, 25, 28, 22, 28, 19, 25, 24, 24)

D57 (n=29, 39, 14, 35, 42) D208 (n=25, 19, 27, 26, 23, 27, 25, 28, 22, 28, 19, 25, 24, 24) D211

(n=29, 39, 14, 35, 42)

Y2 (n=24, 26, 37, 10, 32, 35) Y3 (n=24, 19, 27, 26, 23, 27, 25, 28, 22, 27, 19, 25, 24, 24, 21, 24, 35, 13, 29, 37) Y4

(n=23, 19, 26, 26, 23, 26, 23, 28, 22, 28, 19, 25, 23, 24, 20, 18, 22, 11, 20, 27) Y5

(n=21, 19, 26, 24, 23, 26, 24, 27, 22, 25, 19, 24, 21, 24, 19, 8, 15, 10, 10, 16). 999, 9999, 99999=No participants were analyzed at specific timepoints in NOR-107, NOR-210, NOR-204 respectively.

|  |           |
|--|-----------|
| End point type                         | Secondary |
| End point timeframe:                   |           |
| Up to 5 years post-primary vaccination |           |

| End point values                         | NOR-107: GI.1/GII.4 (15/15/500) µg- MPL 50 µg, 1-Dose | NOR-107: GI.1/GII.4 (15/50/500) µg- MPL 50 µg, 1-Dose | NOR-107: GI.1/GII.4 (50/50/500) µg- MPL 50 µg, 1-Dose | NOR-107: GI.1/GII.4 (15/15/500) µg- MPL 15 µg, 1-Dose |
|--|---|---|---|---|
| Subject group type                       | Reporting group                                       | Reporting group                                       | Reporting group                                       | Reporting group                                       |
| Number of subjects analysed              | 25  | 19  | 27  | 26  |
| Units: titer                             |   |   |   |   |
| geometric mean (confidence interval 95%) |   |   |   |   |
| Baseline                                 | 1030.5 (543.6 to 1953.7)                              | 689.8 (295.3 to 1611.4)                               | 646.2 (354.3 to 1178.4)                               | 620.9 (326.7 to 1180.1)                               |

|         |                              |                             |                              |                             |
|---------|------------------------------|-----------------------------|------------------------------|-----------------------------|
| Day 28  | 975.2 (508.7 to 1869.6)      | 649.3 (285.2 to 1478.2)     | 544.9 (297.5 to 998.3)       | 648.7 (324.3 to 1297.5)     |
| Day 29  | 999 (-999 to 999)            | 999 (-999 to 999)           | 999 (-999 to 999)            | 999 (-999 to 999)           |
| Day 36  | 999 (-999 to 999)            | 999 (-999 to 999)           | 999 (-999 to 999)            | 999 (-999 to 999)           |
| Day 56  | 15032.5 (10033.4 to 22522.2) | 12246.2 (7488.7 to 20025.9) | 16739.1 (11460.0 to 24450.0) | 13673.2 (8411.3 to 22226.9) |
| Day 57  | 999 (-999 to 999)            | 999 (-999 to 999)           | 999 (-999 to 999)            | 999 (-999 to 999)           |
| Day 208 | 6015.9 (4271.9 to 8471.9)    | 4784.5 (3114.9 to 7349.0)   | 6231.0 (4321.0 to 8985.3)    | 5675.5 (3783.7 to 8513.4)   |
| Day 211 | 999 (-999 to 999)            | 999 (-999 to 999)           | 999 (-999 to 999)            | 999 (-999 to 999)           |
| Year 2  | 999 (-999 to 999)            | 999 (-999 to 999)           | 999 (-999 to 999)            | 999 (-999 to 999)           |
| Year 3  | 2229.0 (1481.3 to 3354.1)    | 1493.3 (987.8 to 2257.6)    | 2058.7 (1538.0 to 2755.7)    | 2227.0 (1581.4 to 3136.2)   |
| Year 4  | 2095.5 (1272.0 to 3452.2)    | 1727.7 (1016.1 to 2937.8)   | 2541.1 (1618.3 to 3990.1)    | 1958.2 (1363.0 to 2813.3)   |
| Year 5  | 1732.3 (1133.8 to 2646.8)    | 1563.6 (957.9 to 2552.6)    | 2345.8 (1566.6 to 3512.7)    | 2009.8 (1396.6 to 2892.2)   |

| <b>End point values</b>                  | NOR-107:<br>GI.1/GII.4<br>(15/50/500)<br>µg- MPL 15<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(50/50/500)<br>µg- MPL 15<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(15/15/500)<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/500)<br>µg,1-Dose |
|--|--|--|--|--|
| Subject group type                       | Reporting group  | Reporting group  | Reporting group                                    | Reporting group                                    |
| Number of subjects analysed              | 23   | 27   | 25   | 28   |
| Units: titer                             |  |  |  |  |
| geometric mean (confidence interval 95%) |  |  |  |  |
| Baseline                                 | 547.4 (334.5 to 895.6)   | 539.6 (293.3 to 992.5)   | 1089.2 (599.9 to 1977.6)                           | 856.1 (471.5 to 1554.3)                            |
| Day 28                                   | 475.4 (284.8 to 793.4)   | 535.4 (287.5 to 997.1)   | 1086.1 (613.7 to 1922.0)                           | 839.1 (469.7 to 1499.0)                            |
| Day 29                                   | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)                                  | 999 (-999 to 999)                                  |
| Day 36                                   | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)                                  | 999 (-999 to 999)                                  |
| Day 56                                   | 12847.2 (9036.9 to 18264.2)                                      | 18464.0 (14207.7 to 23995.3)                                     | 15242.3 (11298.2 to 20563.2)                       | 15071.0 (9104.8 to 24946.5)                        |
| Day 57                                   | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)                                  | 999 (-999 to 999)                                  |
| Day 208                                  | 4212.3 (3065.0 to 5789.1)  | 4997.4 (3748.7 to 6662.0)  | 5577.8 (4072.7 to 7639.2)                          | 6686.7 (4766.4 to 9380.5)                          |
| Day 211                                  | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)                                  | 999 (-999 to 999)                                  |
| Year 2                                   | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)                                  | 999 (-999 to 999)                                  |

|        |                           |                           |                           |                           |
|--------|---------------------------|---------------------------|---------------------------|---------------------------|
| Year 3 | 1465.7 (1056.7 to 2032.8) | 1568.0 (1188.6 to 2068.5) | 2156.1 (1527.7 to 3042.9) | 1913.2 (1386.8 to 2639.4) |
| Year 4 | 1802.9 (1185.9 to 2740.8) | 1565.5 (1181.0 to 2075.1) | 2934.1 (1993.0 to 4319.7) | 2107.0 (1384.3 to 3207.0) |
| Year 5 | 1664.8 (1100.7 to 2518.1) | 1781.2 (1102.5 to 2877.7) | 2116.5 (1597.7 to 2803.7) | 2270.3 (1536.1 to 3355.5) |

| End point values                         | NOR-107: GI.1/GII.4 (50/50/500) µg,1-Dose | NOR-107: GI.1/GII.4 (50/150/500) µg,1-Dose | NOR-107: GI.1/GII.4 (15/50/167) µg,1-Dose | NOR-107: GI.1/GII.4 (15/50/500) µg,2-Dose |
|--|---|--|---|---|
| Subject group type                       | Reporting group                           | Reporting group                            | Reporting group                           | Reporting group                           |
| Number of subjects analysed              | 22  | 28   | 19  | 25  |
| Units: titer                             |   |  |   |   |
| geometric mean (confidence interval 95%) |   |  |   |   |
| Baseline                                 | 749.7 (406.6 to 1382.5)                   | 770.6 (413.5 to 1436.2)                    | 925.3 (366.0 to 2339.3)                   | 777.3 (413.1 to 1462.8)                   |
| Day 28                                   | 729.3 (380.1 to 1399.5)                   | 731.0 (382.7 to 1396.2)                    | 932.8 (402.0 to 2164.8)                   | 16822.8 (11052.9 to 25604.9)              |
| Day 29                                   | 999 (-999 to 999)                         | 999 (-999 to 999)                          | 999 (-999 to 999)                         | 999 (-999 to 999)                         |
| Day 36                                   | 999 (-999 to 999)                         | 999 (-999 to 999)                          | 999 (-999 to 999)                         | 999 (-999 to 999)                         |
| Day 56                                   | 25738.6 (16696.8 to 39676.9)              | 14709.3 (10110.9 to 21399.2)               | 12428.4 (6942.7 to 22248.5)               | 14302.9 (10081.6 to 20291.8)              |
| Day 57                                   | 999 (-999 to 999)                         | 999 (-999 to 999)                          | 999 (-999 to 999)                         | 999 (-999 to 999)                         |
| Day 208                                  | 7761.2 (5226.5 to 11525.1)                | 5274.3 (3746.7 to 7424.6)                  | 4978.7 (3275.4 to 7567.6)                 | 7082.7 (5051.7 to 9930.2)                 |
| Day 211                                  | 999 (-999 to 999)                         | 999 (-999 to 999)                          | 999 (-999 to 999)                         | 999 (-999 to 999)                         |
| Year 2                                   | 999 (-999 to 999)                         | 999 (-999 to 999)                          | 999 (-999 to 999)                         | 999 (-999 to 999)                         |
| Year 3                                   | 2063.1 (1370.8 to 3105.0)                 | 1702.4 (1165.5 to 2486.6)                  | 1579.5 (977.5 to 2552.2)                  | 2422.7 (1732.0 to 3388.9)                 |
| Year 4                                   | 1965.0 (1287.9 to 2997.9)                 | 1679.0 (1208.0 to 2333.5)                  | 2025.2 (1254.9 to 3268.3)                 | 2335.8 (1724.4 to 3163.8)                 |
| Year 5                                   | 2181.9 (1360.4 to 3499.2)                 | 1811.9 (1173.5 to 2797.8)                  | 1434.9 (956.9 to 2151.6)                  | 2036.9 (1475.0 to 2812.9)                 |

| End point values            | NOR-107: GI.1/GII.4 (50/150/500) µg,2-Dose | NOR-107: GI.1/GII.4 (15/50/167) µg,2-Dose | NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose | NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose |
|-----------------------------|--|---|--|--|
| Subject group type          | Reporting group                            | Reporting group                           | Reporting group                            | Reporting group                            |
| Number of subjects analysed | 24   | 24  | 24   | 29   |

|  |                              |                             |                             |                             |  |
|--|------------------------------|-----------------------------|-----------------------------|-----------------------------|--|
| Units: titer                             |                              |                             |                             |                             |  |
| geometric mean (confidence interval 95%) |                              |                             |                             |                             |  |
| Baseline                                 | 908.6 (501.0 to 1647.8)      | 640.4 (378.5 to 1083.5)     | 160.1 (78.6 to 326.1)       | 671.5 (432.5 to 1042.4)     |  |
| Day 28                                   | 21215.2 (15921.0 to 28269.9) | 14102.7 (9666.5 to 20574.8) | 9999 (-9999 to 9999)        | 99999 (-99999 to 99999)     |  |
| Day 29                                   | 999 (-999 to 999)            | 999 (-999 to 999)           | 10798.6 (7482.3 to 15584.8) | 630.6 (407.9 to 974.8)      |  |
| Day 36                                   | 999 (-999 to 999)            | 999 (-999 to 999)           | 9999 (-9999 to 9999)        | 6915.9 (4770.3 to 10026.5)  |  |
| Day 56                                   | 18086.8 (13594.7 to 24063.2) | 11282.4 (8142.8 to 15632.5) | 9999 (-9999 to 9999)        | 99999 (-99999 to 99999)     |  |
| Day 57                                   | 999 (-999 to 999)            | 999 (-999 to 999)           | 9999 (-9999 to 9999)        | 10684.3 (8532.4 to 13378.9) |  |
| Day 208                                  | 7469.9 (5874.5 to 9498.6)    | 5355.9 (4082.7 to 7026.2)   | 9999 (-9999 to 9999)        | 99999 (-99999 to 99999)     |  |
| Day 211                                  | 999 (-999 to 999)            | 999 (-999 to 999)           | 9999 (-9999 to 9999)        | 5970.0 (4586.1 to 7771.7)   |  |
| Year 2                                   | 999 (-999 to 999)            | 999 (-999 to 999)           | 1662.0 (1203.1 to 2296.0)   | 1804.4 (1405.6 to 2316.4)   |  |
| Year 3                                   | 2914.8 (2270.4 to 3742.1)    | 2077.8 (1523.3 to 2834.1)   | 1500.9 (1031.3 to 2184.2)   | 2006.4 (1373.3 to 2931.3)   |  |
| Year 4                                   | 2635.7 (1936.2 to 3587.9)    | 2016.6 (1500.0 to 2711.1)   | 1627.4 (1127.0 to 2350.1)   | 1512.1 (1032.5 to 2214.6)   |  |
| Year 5                                   | 2405.4 (1763.1 to 3281.8)    | 1817.7 (1256.1 to 2630.5)   | 1803.8 (1205.4 to 2699.1)   | 1937.4 (1141.5 to 3288.2)   |  |

|  |   |   |   |  |
|--|---|---|---|--|
| <b>End point values</b>                  | NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs) | NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs) | NOR-204: GI.1/GII.4 (15/50/500/15) µg - MPL 15 µg, 2-Dose | NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose |
| Subject group type                       | Reporting group   | Reporting group   | Reporting group   | Reporting group                            |
| Number of subjects analysed              | 39  | 14  | 35  | 42   |
| Units: titer                             |   |   |   |  |
| geometric mean (confidence interval 95%) |   |   |   |  |
| Baseline                                 | 769.8 (559.5 to 1059.0)                                     | 493.1 (170.7 to 1424.8)                                     | 683.8 (460.7 to 1014.9)                                   | 851.8 (534.3 to 1357.9)                    |
| Day 28                                   | 99999 (-99999 to 99999)                                     | 99999 (-99999 to 99999)                                     | 99999 (-99999 to 99999)                                   | 99999 (-99999 to 99999)                    |
| Day 29                                   | 734.8 (544.2 to 992.1)                                      | 694.7 (249.8 to 1931.4)                                     | 10862.2 (8363.3 to 14107.7)                               | 8286.7 (6204.3 to 11068.0)                 |
| Day 36                                   | 3909.4 (2555.3 to 5981.0)                                   | 7407.6 (3545.0 to 15479.0)                                  | 10851.2 (8549.3 to 13772.9)                               | 8143.0 (6132.6 to 10812.4)                 |



|         |                           |                            |                            |                           |
|---------|---------------------------|----------------------------|----------------------------|---------------------------|
| Day 56  | 99999 (-99999 to 99999)   | 99999 (-99999 to 99999)    | 99999 (-99999 to 99999)    | 99999 (-99999 to 99999)   |
| Day 57  | 5646.8 (4043.4 to 7886.1) | 7944.8 (4570.2 to 13811.2) | 9388.2 (7285.3 to 12098.2) | 7316.3 (5685.6 to 9414.7) |
| Day 208 | 99999 (-99999 to 99999)   | 99999 (-99999 to 99999)    | 99999 (-99999 to 99999)    | 99999 (-99999 to 99999)   |
| Day 211 | 4137.3 (3176.2 to 5389.2) | 3745.8 (1975.8 to 7101.5)  | 5320.5 (4169.4 to 6789.4)  | 5020.4 (3878.5 to 6498.6) |
| Year 2  | 1477.4 (1016.3 to 2147.7) | 1672.4 (656.0 to 4263.7)   | 1770.6 (1310.4 to 2392.3)  | 1635.0 (1194.2 to 2238.4) |
| Year 3  | 1932.8 (1245.7 to 2998.7) | 1254.9 (701.7 to 2244.2)   | 1670.1 (1258.5 to 2216.4)  | 1700.5 (1224.7 to 2361.3) |
| Year 4  | 1441.7 (926.9 to 2242.4)  | 1238.3 (841.5 to 1822.1)   | 1585.6 (1101.6 to 2282.3)  | 1392.4 (917.6 to 2112.9)  |
| Year 5  | 1255.5 (709.1 to 2223.1)  | 1048.6 (566.7 to 1940.4)   | 2060.5 (1422.7 to 2984.3)  | 1687.2 (1031.7 to 2759.3) |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as measured by pan-Ig ELISA

|                 |  |
|-----------------|--|
| End point title | Geometric Mean Titers (GMT) of Anti-norovirus GII.4 VLP Antibodies as measured by pan-Ig ELISA |
|-----------------|--|

End point description:

GMT of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA. Data reported for up to Year 5 was collected at Baseline, Days 28, 29, 36, 56, 57, 208, 211 Year 2, 3, 4, and 5. PPS=all participants in FAS who had no major or critical protocol violations. n=number of participants with data available for analysis at specific timepoints. Baseline (n=25, 19, 27, 26, 23, 27, 25, 28, 22, 28, 19, 25, 24, 24, 24, 29, 39, 14, 35, 42) D28 (n=25, 19, 26, 26, 23, 27, 25, 28, 21, 28, 19, 25, 24, 24) D29 (n=24, 29, 39, 14, 35, 42) D36 (n=29, 39, 14, 35, 42) D56 (n=25, 19, 27, 26, 23, 27, 25, 28, 22, 28, 19, 25, 24, 24) D57 (n=29, 39, 14, 35, 42) D208 (n=25, 19, 27, 26, 23, 27, 25, 28, 22, 28, 19, 25, 24, 24) D211 (n=29, 39, 14, 35, 42) Y2 (n=24, 26, 37, 10, 32, 35) Y3 (n=24, 19, 27, 26, 23, 27, 25, 28, 22, 27, 19, 25, 24, 24, 21, 24, 35, 13, 29, 37) Y4 (n=23, 19, 26, 26, 23, 26, 23, 28, 22, 28, 19, 25, 23, 24, 20, 18, 22, 11, 20, 27) Y5 (n=21, 19, 26, 24, 23, 26, 24, 27, 22, 25, 19, 24, 21, 24, 19, 8, 15, 10, 10, 17). 999, 9999, 99999=No participants were analyzed at specific timepoints in NOR-107, NOR-210, NOR-204 respectively.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 5 years post-primary vaccination

| End point values                         | NOR-107:<br>GI.1/GII.4<br>(15/15/500)<br>µg- MPL 50<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/500)<br>µg- MPL 50<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(50/50/500)<br>µg- MPL 50<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(15/15/500)<br>µg- MPL 15<br>µg,1-Dose |
|--|--|--|--|--|
| Subject group type                       | Reporting group  | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 25   | 19   | 27   | 26   |
| Units: titer                             |  |  |  |  |
| geometric mean (confidence interval 95%) |  |  |  |  |
| Baseline                                 | 1209.8 (617.2 to 2371.5)   | 1248.3 (665.1 to 2343.0)   | 1423.3 (799.5 to 2533.7)   | 954.0 (530.1 to 1716.8)  |
| Day 28                                   | 1218.3 (609.8 to 2433.7)   | 1233.2 (658.4 to 2309.7)   | 1471.1 (841.2 to 2572.7)   | 953.8 (549.5 to 1655.4)  |
| Day 29                                   | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  |
| Day 36                                   | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  |
| Day 56                                   | 5051.3 (3144.0 to 8115.7)  | 8644.5 (6368.1 to 11734.7)                                       | 5651.7 (4159.3 to 7679.4)  | 3909.2 (2620.5 to 5831.7)  |
| Day 57                                   | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  |
| Day 208                                  | 2805.0 (1665.3 to 4724.8)  | 3797.7 (2654.3 to 5433.8)  | 2757.9 (1631.0 to 4663.4)  | 2575.3 (1695.6 to 3911.3)  |
| Day 211                                  | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  |
| Year 2                                   | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)  |
| Year 3                                   | 1643.9 (850.8 to 3176.6)   | 1874.7 (1066.5 to 3295.6)  | 1756.7 (1193.6 to 2585.3)  | 1159.4 (731.0 to 1838.7)   |
| Year 4                                   | 1580.2 (856.2 to 2916.6)   | 2128.6 (1214.1 to 3732.0)  | 1828.6 (1183.6 to 2825.2)  | 1234.2 (791.8 to 1923.6)   |
| Year 5                                   | 1159.9 (587.5 to 2289.8)   | 2232.6 (1270.8 to 3922.1)  | 1702.6 (1091.4 to 2656.0)  | 1135.0 (709.5 to 1815.7)   |

| End point values                         | NOR-107:<br>GI.1/GII.4<br>(15/50/500)<br>µg- MPL 15<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(50/50/500)<br>µg- MPL 15<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(15/15/500)<br>µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/500)<br>µg,1-Dose |
|--|--|--|--|--|
| Subject group type                       | Reporting group  | Reporting group  | Reporting group                                    | Reporting group                                    |
| Number of subjects analysed              | 23   | 27   | 25   | 28   |
| Units: titer                             |  |  |  |  |
| geometric mean (confidence interval 95%) |  |  |  |  |
| Baseline                                 | 838.8 (507.6 to 1386.1)  | 1239.7 (705.8 to 2177.4)   | 1373.7 (792.4 to 2381.6)                           | 1179.5 (677.5 to 2053.4)                           |
| Day 28                                   | 754.4 (464.2 to 1226.0)  | 1198.8 (688.3 to 2088.0)   | 1310.7 (797.3 to 2154.5)                           | 1246.3 (710.3 to 2187.0)                           |
| Day 29                                   | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)                                  | 999 (-999 to 999)                                  |
| Day 36                                   | 999 (-999 to 999)  | 999 (-999 to 999)  | 999 (-999 to 999)                                  | 999 (-999 to 999)                                  |

|         |                           |                            |                           |                            |
|---------|---------------------------|----------------------------|---------------------------|----------------------------|
| Day 56  | 6655.7 (4670.1 to 9485.5) | 7585.7 (5687.6 to 10117.3) | 3296.3 (2075.7 to 5234.7) | 9110.9 (5865.5 to 14152.2) |
| Day 57  | 999 (-999 to 999)         | 999 (-999 to 999)          | 999 (-999 to 999)         | 999 (-999 to 999)          |
| Day 208 | 2861.7 (2000.7 to 4093.2) | 3086.6 (2194.7 to 4341.0)  | 2239.3 (1451.7 to 3454.4) | 4668.9 (3069.6 to 7101.4)  |
| Day 211 | 999 (-999 to 999)         | 999 (-999 to 999)          | 999 (-999 to 999)         | 999 (-999 to 999)          |
| Year 2  | 999 (-999 to 999)         | 999 (-999 to 999)          | 999 (-999 to 999)         | 999 (-999 to 999)          |
| Year 3  | 1193.5 (780.4 to 1825.4)  | 1385.2 (946.0 to 2028.2)   | 1425.3 (844.2 to 2406.6)  | 1705.3 (1024.2 to 2839.3)  |
| Year 4  | 1283.8 (870.2 to 1894.0)  | 1714.5 (1133.1 to 2594.2)  | 2114.3 (1369.8 to 3263.4) | 1858.2 (1107.6 to 3117.5)  |
| Year 5  | 1177.1 (774.7 to 1788.5)  | 1545.6 (952.6 to 2507.9)   | 1410.6 (927.5 to 2145.5)  | 2047.9 (1097.6 to 3821.1)  |

| End point values                         | NOR-107: GI.1/GII.4 (50/50/500) µg,1-Dose | NOR-107: GI.1/GII.4 (50/150/500) µg,1-Dose | NOR-107: GI.1/GII.4 (15/50/167) µg,1-Dose | NOR-107: GI.1/GII.4 (15/50/500) µg,2-Dose |
|--|---|--|---|---|
| Subject group type                       | Reporting group                           | Reporting group                            | Reporting group                           | Reporting group                           |
| Number of subjects analysed              | 22  | 28   | 19  | 25  |
| Units: titer                             |   |  |   |   |
| geometric mean (confidence interval 95%) |   |  |   |   |
| Baseline                                 | 1133.9 (648.4 to 1982.8)                  | 1442.1 (864.3 to 2406.1)                   | 2069.2 (1362.0 to 3143.7)                 | 1078.9 (678.4 to 1715.6)                  |
| Day 28                                   | 1086.0 (619.5 to 1903.7)                  | 1491.7 (983.7 to 2262.0)                   | 1940.6 (1259.0 to 2991.2)                 | 8866.0 (6415.5 to 12252.6)                |
| Day 29                                   | 999 (-999 to 999)                         | 999 (-999 to 999)                          | 999 (-999 to 999)                         | 999 (-999 to 999)                         |
| Day 36                                   | 999 (-999 to 999)                         | 999 (-999 to 999)                          | 999 (-999 to 999)                         | 999 (-999 to 999)                         |
| Day 56                                   | 4762.7 (2918.8 to 7771.4)                 | 10733.0 (7902.0 to 14578.1)                | 9544.8 (6846.7 to 13306.1)                | 7083.6 (5125.3 to 9790.1)                 |
| Day 57                                   | 999 (-999 to 999)                         | 999 (-999 to 999)                          | 999 (-999 to 999)                         | 999 (-999 to 999)                         |
| Day 208                                  | 2349.9 (1405.2 to 3929.8)                 | 4661.9 (3401.9 to 6388.5)                  | 4450.1 (2994.6 to 6613.0)                 | 4004.2 (2834.4 to 5656.7)                 |
| Day 211                                  | 999 (-999 to 999)                         | 999 (-999 to 999)                          | 999 (-999 to 999)                         | 999 (-999 to 999)                         |
| Year 2                                   | 999 (-999 to 999)                         | 999 (-999 to 999)                          | 999 (-999 to 999)                         | 999 (-999 to 999)                         |
| Year 3                                   | 1166.5 (608.1 to 2237.6)                  | 1775.4 (1208.6 to 2608.1)                  | 1783.7 (1093.8 to 2909.0)                 | 1880.8 (1254.3 to 2820.4)                 |
| Year 4                                   | 1115.2 (597.5 to 2081.7)                  | 1762.5 (1170.1 to 2655.0)                  | 2173.9 (1287.5 to 3670.6)                 | 1702.1 (976.9 to 2965.5)                  |

|        |                          |                           |                          |                           |
|--------|--------------------------|---------------------------|--------------------------|---------------------------|
| Year 5 | 1265.5 (682.2 to 2347.3) | 2037.4 (1364.0 to 3043.1) | 1648.1 (989.0 to 2746.2) | 1746.6 (1149.0 to 2655.0) |
|--------|--------------------------|---------------------------|--------------------------|---------------------------|

| End point values                         | NOR-107:<br>GI.1/GII.4<br>(50/150/500)<br>µg, 2-Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/167)<br>µg, 2-Dose | NOR-210:<br>GI.1/GII.4<br>(15/50/500)<br>µg, 1-Dose | NOR-204:<br>GI.1/GII.4<br>(15/50/500)<br>µg, 1-Dose |
|--|--|---|---|---|
| Subject group type                       | Reporting group                                      | Reporting group                                     | Reporting group                                     | Reporting group                                     |
| Number of subjects analysed              | 24   | 24  | 24  | 29  |
| Units: titer                             |  |   |   |   |
| geometric mean (confidence interval 95%) |  |   |   |   |
| Baseline                                 | 1308.9 (779.3 to 2198.4)                             | 1598.5 (952.6 to 2682.3)                            | 93.1 (58.8 to 147.3)                                | 1213.2 (658.2 to 2236.1)                            |
| Day 28                                   | 13710.2 (10111.0 to 18590.5)                         | 10202.3 (6715.1 to 15500.5)                         | 9999 (-9999 to 9999)                                | 99999 (-99999 to 99999)                             |
| Day 29                                   | 999 (-999 to 999)                                    | 999 (-999 to 999)                                   | 10170.0 (7301.6 to 14165.2)                         | 1172.6 (630.4 to 2181.1)                            |
| Day 36                                   | 999 (-999 to 999)                                    | 999 (-999 to 999)                                   | 9999 (-9999 to 9999)                                | 5938.0 (3771.8 to 9348.2)                           |
| Day 56                                   | 10333.3 (7485.5 to 14264.4)                          | 7801.7 (5379.1 to 11315.4)                          | 9999 (-9999 to 9999)                                | 99999 (-99999 to 99999)                             |
| Day 57                                   | 999 (-999 to 999)                                    | 999 (-999 to 999)                                   | 9999 (-9999 to 9999)                                | 9761.9 (6487.9 to 14688.1)                          |
| Day 208                                  | 4807.4 (3225.4 to 7165.3)                            | 4177.3 (2914.0 to 5988.2)                           | 9999 (-9999 to 9999)                                | 99999 (-99999 to 99999)                             |
| Day 211                                  | 999 (-999 to 999)                                    | 999 (-999 to 999)                                   | 9999 (-9999 to 9999)                                | 5710.0 (3654.0 to 8922.7)                           |
| Year 2                                   | 999 (-999 to 999)                                    | 999 (-999 to 999)                                   | 1513.3 (897.0 to 2553.2)                            | 2344.8 (1508.6 to 3644.5)                           |
| Year 3                                   | 2079.5 (1465.2 to 2951.4)                            | 1946.0 (1303.7 to 2904.8)                           | 1202.9 (682.0 to 2121.6)                            | 2200.3 (1284.6 to 3768.8)                           |
| Year 4                                   | 2766.1 (1630.1 to 4694.0)                            | 2044.1 (1416.3 to 2950.2)                           | 1254.0 (743.5 to 2115.0)                            | 1514.3 (895.9 to 2559.5)                            |
| Year 5                                   | 2225.0 (1305.9 to 3791.0)                            | 1624.0 (1073.2 to 2457.7)                           | 1241.5 (726.4 to 2121.8)                            | 1076.0 (406.2 to 2850.3)                            |

| End point values            | NOR-204:<br>GI.1/GII.4<br>(15/50/500)<br>µg, 1-Dose<br>(Age: 60-94<br>Yrs) | NOR-204:<br>GI.1/GII.4<br>(15/50/500)<br>µg, 1-Dose<br>(Age: 18-49<br>Yrs) | NOR-204:<br>GI.1/GII.4<br>(15/50/500/15)<br>µg - MPL 15<br>µg, 2-Dose | NOR-204:<br>GI.1/GII.4<br>(15/50/500)<br>µg, 2-Dose |
|-----------------------------|--|--|---|---|
| Subject group type          | Reporting group  | Reporting group  | Reporting group   | Reporting group                                     |
| Number of subjects analysed | 39   | 14   | 35  | 42  |

|  |                           |                            |                            |                            |  |
|--|---------------------------|----------------------------|----------------------------|----------------------------|--|
| Units: titer                             |                           |                            |                            |                            |  |
| geometric mean (confidence interval 95%) |                           |                            |                            |                            |  |
| Baseline                                 | 826.1 (508.7 to 1341.7)   | 1288.0 (570.8 to 2906.4)   | 1263.5 (794.7 to 2009.0)   | 1149.0 (672.9 to 1961.8)   |  |
| Day 28                                   | 99999 (-99999 to 99999)   | 99999 (-99999 to 99999)    | 99999 (-99999 to 99999)    | 99999 (-99999 to 99999)    |  |
| Day 29                                   | 818.6 (510.4 to 1313.0)   | 1251.3 (563.1 to 2780.5)   | 9284.7 (6772.0 to 12729.9) | 8508.2 (5798.6 to 12484.1) |  |
| Day 36                                   | 4248.1 (2787.2 to 6474.8) | 8348.3 (5370.9 to 12976.3) | 9415.5 (7120.6 to 12450.1) | 8518.7 (5970.1 to 12155.2) |  |
| Day 56                                   | 99999 (-99999 to 99999)   | 99999 (-99999 to 99999)    | 99999 (-99999 to 99999)    | 99999 (-99999 to 99999)    |  |
| Day 57                                   | 5961.1 (4365.7 to 8139.7) | 8689.8 (6309.5 to 11968.1) | 7673.7 (5733.9 to 10269.7) | 7610.5 (5336.3 to 10854.0) |  |
| Day 208                                  | 99999 (-99999 to 99999)   | 99999 (-99999 to 99999)    | 99999 (-99999 to 99999)    | 99999 (-99999 to 99999)    |  |
| Day 211                                  | 3949.0 (2991.2 to 5213.6) | 4825.8 (3063.2 to 7602.6)  | 5389.0 (4070.1 to 7135.2)  | 5415.4 (3633.4 to 8071.3)  |  |
| Year 2                                   | 1465.5 (1039.9 to 2065.3) | 4160.4 (1968.6 to 8792.4)  | 2244.0 (1462.9 to 3442.1)  | 2380.4 (1507.4 to 3759.2)  |  |
| Year 3                                   | 1771.1 (1276.4 to 2457.6) | 2155.0 (1293.4 to 3590.8)  | 2297.5 (1422.8 to 3709.9)  | 2304.2 (1369.0 to 3878.4)  |  |
| Year 4                                   | 1267.2 (788.9 to 2035.5)  | 1806.5 (1032.7 to 3160.1)  | 2466.9 (1489.0 to 4086.9)  | 1823.5 (1089.5 to 3052.0)  |  |
| Year 5                                   | 912.7 (529.7 to 1572.6)   | 1187.7 (680.8 to 2071.8)   | 1522.7 (936.1 to 2476.8)   | 2097.3 (1285.7 to 3421.1)  |  |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information<sup>[1]</sup>

Timeframe for reporting adverse events:

From the time of informed consent signed up to end of the study (Up to approximately 5 years)

Adverse event reporting additional description:

At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 24.0 |
|--------------------|------|

### Reporting groups

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-107: GI.1/GII.4 (15/50/500) µg- MPL 50 µg,1-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-107: GI.1/GII.4 (15/15/500) µg- MPL 50 µg,1-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus virus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-107: GI.1/GII.4 (50/50/500) µg- MPL 50 µg,1-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-107: GI.1/GII.4 (15/15/500) µg- MPL 15 µg,1-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-107: GI.1/GII.4 (15/50/500) µg- MPL 15 µg,1-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-107 participants who had received IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-107: GI.1/GII.4 (50/50/500) µg- MPL 15 µg,1-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-107 participants who received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-107: GI.1/GII.4 (15/15/500) µg,1-Dose |
|-----------------------|---|

Reporting group description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-107: GI.1/GII.4 (50/50/500) µg,1-Dose |
|-----------------------|---|

Reporting group description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-107: GI.1/GII.4 (15/50/500) µg,1-Dose |
|-----------------------|---|

Reporting group description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-107: GI.1/GII.4 (50/150/500) µg,1-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-217 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-107: GI.1/GII.4 (15/50/167) µg,1-Dose |
|-----------------------|---|

Reporting group description:

Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-107: GI.1/GII.4 (15/50/500) µg,2-Dose |
|-----------------------|---|

Reporting group description:

Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-107: GI.1/GII.4 (50/150/500) µg,2-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-107: GI.1/GII.4 (15/50/167) µg,1-Dose |
|-----------------------|---|

Reporting group description:

Eligible NOR-217 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-210 participants who had received Norovirus GI.1/GII.4 bivalent VLP vaccine NoV Vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP, adjuvanted with 500 µg aluminium hydroxide), IM injection, once on Day 1 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-204: GI.1/GII.4 (15/50/500/15) µg, 1-Dose |
|-----------------------|---|

Reporting group description:

Eligible NOR-204 participants who had received Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) [15 µg of GI.1 and 50 µg of GII.4 bivalent virus-like particle (VLP)] adjuvanted with 500 µg aluminium hydroxide and 15 µg of monophosphoryl lipid A (MPL) (Composition B), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 Yrs) |
|-----------------------|---|

Reporting group description:

Eligible NOR-204 participants of age 60-94 years who had received Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus (NoV) [15 µg of GI.1 and 50 µg of GII.4 bivalent virus-like particle (VLP)] adjuvanted with 500 µg aluminium hydroxide (Composition A), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 Yrs) |
|-----------------------|---|

Reporting group description:

Eligible NOR-204 participants of age 18-49 years who had received Norovirus bivalent placebo-matching

vaccine, IM, on Day 1, followed by norovirus (NoV) [15 µg of GI.1 and 50 µg of GII.4 bivalent virus-like particle (VLP)] adjuvanted with 500 µg aluminium hydroxide (Composition A), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|                       |   |
|-----------------------|---|
| Reporting group title | NOR-204: GI.1/GII.4 (15/50/500/15) µg - MPL 15 µg, 2-Dose |
|-----------------------|---|

Reporting group description:

Eligible NOR-204 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide and 15 µg of MPL (Composition B), IM, on Day 1 and Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

|                       |  |
|-----------------------|--|
| Reporting group title | NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose |
|-----------------------|--|

Reporting group description:

Eligible NOR-204 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 50 µg of GII.4 bivalent VLP) adjuvanted with 500 µg aluminium hydroxide (Composition A) IM, on Day 1 and Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: No non-serious adverse events were reported in this study.

| Serious adverse events  | NOR-107:<br>GI.1/GII.4<br>(15/50/500) µg- | NOR-107: GI.1/GII.4<br>(15/15/500) µg-<br>MPL 50 µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(50/50/500) µg- |
|---|---|--|---|
| Total subjects affected by serious adverse events                   |   |  |   |
| subjects affected / exposed   | 1 / 27 (3.70%)                            | 0 / 25 (0.00%)   | 1 / 19 (5.26%)                            |
| number of deaths (all causes)                                       | 0   | 0  | 0   |
| number of deaths resulting from adverse events                      | 0   | 0  | 0   |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |   |  |   |
| Metastases to lung  |   |  |   |
| subjects affected / exposed   | 0 / 27 (0.00%)                            | 0 / 25 (0.00%)   | 0 / 19 (0.00%)                            |
| occurrences causally related to treatment / all                     | 0 / 0                                     | 0 / 0  | 0 / 0                                     |
| deaths causally related to treatment / all                          | 0 / 0                                     | 0 / 0  | 0 / 0                                     |
| Metastatic renal cell carcinoma                                     |   |  |   |
| subjects affected / exposed   | 0 / 27 (0.00%)                            | 0 / 25 (0.00%)   | 0 / 19 (0.00%)                            |
| occurrences causally related to treatment / all                     | 0 / 0                                     | 0 / 0  | 0 / 0                                     |
| deaths causally related to treatment / all                          | 0 / 0                                     | 0 / 0  | 0 / 0                                     |
| Squamous cell carcinoma of the tongue                               |   |  |   |
| subjects affected / exposed   | 0 / 27 (0.00%)                            | 0 / 25 (0.00%)   | 0 / 19 (0.00%)                            |
| occurrences causally related to treatment / all                     | 0 / 0                                     | 0 / 0  | 0 / 0                                     |
| deaths causally related to treatment / all                          | 0 / 0                                     | 0 / 0  | 0 / 0                                     |
| Injury, poisoning and procedural complications                      |   |  |   |
| Fall  |   |  |   |



|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 25 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Subdural haematoma                              |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 25 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                |                |                |
| Arteriosclerosis coronary artery                |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 25 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac failure congestive                      |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 25 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Coronary artery disease                         |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 25 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Nervous system disorders                        |                |                |                |
| Neurodegenerative disorder                      |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 25 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Eye disorders                                   |                |                |                |
| Amaurosis fugax                                 |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 25 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Episcleritis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 25 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

|   |                |                |                |
|---|----------------|----------------|----------------|
| Gastrointestinal disorders                      |                |                |                |
| Colitis ulcerative                              |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 25 (0.00%) | 1 / 19 (5.26%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Crohn's disease                                 |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 25 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders |                |                |                |
| Pulmonary embolism                              |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 25 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory failure                             |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 25 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                |                |
| Polymyalgia rheumatica                          |                |                |                |
| subjects affected / exposed                     | 1 / 27 (3.70%) | 0 / 25 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| Appendicitis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 25 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pneumonia                                       |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 25 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Sepsis  |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 25 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Metabolism and nutrition disorders              |                |                |                |
| Adult failure to thrive                         |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 25 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

| <b>Serious adverse events</b>                                       | NOR-107:<br>GI.1/GII.4<br>(15/15/500) µg- | NOR-107: GI.1/GII.4<br>(15/50/500) µg-<br>MPL 15 µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(50/50/500) µg- |
|---|---|--|---|
| Total subjects affected by serious adverse events                   |   |  |   |
| subjects affected / exposed   | 1 / 27 (3.70%)                            | 0 / 23 (0.00%)   | 0 / 27 (0.00%)                            |
| number of deaths (all causes)                                       | 0   | 0  | 0   |
| number of deaths resulting from adverse events                      | 0   | 0  | 0   |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |   |  |   |
| Metastases to lung  |   |  |   |
| subjects affected / exposed   | 0 / 27 (0.00%)                            | 0 / 23 (0.00%)   | 0 / 27 (0.00%)                            |
| occurrences causally related to treatment / all                     | 0 / 0                                     | 0 / 0  | 0 / 0                                     |
| deaths causally related to treatment / all                          | 0 / 0                                     | 0 / 0  | 0 / 0                                     |
| Metastatic renal cell carcinoma                                     |   |  |   |
| subjects affected / exposed   | 0 / 27 (0.00%)                            | 0 / 23 (0.00%)   | 0 / 27 (0.00%)                            |
| occurrences causally related to treatment / all                     | 0 / 0                                     | 0 / 0  | 0 / 0                                     |
| deaths causally related to treatment / all                          | 0 / 0                                     | 0 / 0  | 0 / 0                                     |
| Squamous cell carcinoma of the tongue                               |   |  |   |
| subjects affected / exposed   | 0 / 27 (0.00%)                            | 0 / 23 (0.00%)   | 0 / 27 (0.00%)                            |
| occurrences causally related to treatment / all                     | 0 / 0                                     | 0 / 0  | 0 / 0                                     |
| deaths causally related to treatment / all                          | 0 / 0                                     | 0 / 0  | 0 / 0                                     |
| Injury, poisoning and procedural complications                      |   |  |   |
| Fall  |   |  |   |
| subjects affected / exposed   | 0 / 27 (0.00%)                            | 0 / 23 (0.00%)   | 0 / 27 (0.00%)                            |
| occurrences causally related to treatment / all                     | 0 / 0                                     | 0 / 0  | 0 / 0                                     |
| deaths causally related to treatment / all                          | 0 / 0                                     | 0 / 0  | 0 / 0                                     |
| Subdural haematoma  |   |  |   |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 23 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                |                |                |
| Arteriosclerosis coronary artery                |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 23 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac failure congestive                      |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 23 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Coronary artery disease                         |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 23 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Nervous system disorders                        |                |                |                |
| Neurodegenerative disorder                      |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 23 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Eye disorders                                   |                |                |                |
| Amaurosis fugax                                 |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 23 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Episcleritis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 23 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                      |                |                |                |
| Colitis ulcerative                              |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 23 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Crohn's disease                                 |                |                |                |
| subjects affected / exposed                     | 1 / 27 (3.70%) | 0 / 23 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders |                |                |                |
| Pulmonary embolism                              |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 23 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory failure                             |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 23 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                |                |
| Polymyalgia rheumatica                          |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 23 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| Appendicitis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 23 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pneumonia                                       |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 23 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Sepsis  |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 23 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Metabolism and nutrition disorders              |                |                |                |
| Adult failure to thrive                         |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 0 / 23 (0.00%) | 0 / 27 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

| <b>Serious adverse events</b>                                       | NOR-107:<br>GI.1/GII.4<br>(15/15/500) µg,1- | NOR-107: GI.1/GII.4<br>(50/50/500) µg,1-<br>Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/500) µg,1- |
|---|---|--|---|
| Total subjects affected by serious adverse events                   |   |  |   |
| subjects affected / exposed   | 0 / 22 (0.00%)                              | 0 / 25 (0.00%)                                   | 0 / 28 (0.00%)                              |
| number of deaths (all causes)                                       | 0   | 0  | 0   |
| number of deaths resulting from adverse events                      | 0   | 0  | 0   |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |   |  |   |
| Metastases to lung  |   |  |   |
| subjects affected / exposed   | 0 / 22 (0.00%)                              | 0 / 25 (0.00%)                                   | 0 / 28 (0.00%)                              |
| occurrences causally related to treatment / all                     | 0 / 0                                       | 0 / 0  | 0 / 0                                       |
| deaths causally related to treatment / all                          | 0 / 0                                       | 0 / 0  | 0 / 0                                       |
| Metastatic renal cell carcinoma                                     |   |  |   |
| subjects affected / exposed   | 0 / 22 (0.00%)                              | 0 / 25 (0.00%)                                   | 0 / 28 (0.00%)                              |
| occurrences causally related to treatment / all                     | 0 / 0                                       | 0 / 0  | 0 / 0                                       |
| deaths causally related to treatment / all                          | 0 / 0                                       | 0 / 0  | 0 / 0                                       |
| Squamous cell carcinoma of the tongue                               |   |  |   |
| subjects affected / exposed   | 0 / 22 (0.00%)                              | 0 / 25 (0.00%)                                   | 0 / 28 (0.00%)                              |
| occurrences causally related to treatment / all                     | 0 / 0                                       | 0 / 0  | 0 / 0                                       |
| deaths causally related to treatment / all                          | 0 / 0                                       | 0 / 0  | 0 / 0                                       |
| Injury, poisoning and procedural complications                      |   |  |   |
| Fall  |   |  |   |
| subjects affected / exposed   | 0 / 22 (0.00%)                              | 0 / 25 (0.00%)                                   | 0 / 28 (0.00%)                              |
| occurrences causally related to treatment / all                     | 0 / 0                                       | 0 / 0  | 0 / 0                                       |
| deaths causally related to treatment / all                          | 0 / 0                                       | 0 / 0  | 0 / 0                                       |
| Subdural haematoma  |   |  |   |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 25 (0.00%) | 0 / 28 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                |                |                |
| Arteriosclerosis coronary artery                |                |                |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 25 (0.00%) | 0 / 28 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac failure congestive                      |                |                |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 25 (0.00%) | 0 / 28 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Coronary artery disease                         |                |                |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 25 (0.00%) | 0 / 28 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Nervous system disorders                        |                |                |                |
| Neurodegenerative disorder                      |                |                |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 25 (0.00%) | 0 / 28 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Eye disorders                                   |                |                |                |
| Amaurosis fugax                                 |                |                |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 25 (0.00%) | 0 / 28 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Episcleritis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 25 (0.00%) | 0 / 28 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                      |                |                |                |
| Colitis ulcerative                              |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 25 (0.00%) | 0 / 28 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Crohn's disease                                 |                |                |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 25 (0.00%) | 0 / 28 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders |                |                |                |
| Pulmonary embolism                              |                |                |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 25 (0.00%) | 0 / 28 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory failure                             |                |                |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 25 (0.00%) | 0 / 28 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                |                |
| Polymyalgia rheumatica                          |                |                |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 25 (0.00%) | 0 / 28 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| Appendicitis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 25 (0.00%) | 0 / 28 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pneumonia                                       |                |                |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 25 (0.00%) | 0 / 28 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Sepsis  |                |                |                |



|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 25 (0.00%) | 0 / 28 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Metabolism and nutrition disorders              |                |                |                |
| Adult failure to thrive                         |                |                |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 25 (0.00%) | 0 / 28 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

| <b>Serious adverse events</b>                                       | NOR-107:<br>GI.1/GII.4<br>(50/150/500) µg,1- | NOR-107: GI.1/GII.4<br>(15/50/167) µg,1-<br>Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/500) µg,2- |
|---|--|--|---|
| Total subjects affected by serious adverse events                   |  |  |   |
| subjects affected / exposed   | 0 / 28 (0.00%)                               | 0 / 24 (0.00%)                                   | 0 / 24 (0.00%)                              |
| number of deaths (all causes)                                       | 0  | 0  | 0   |
| number of deaths resulting from adverse events                      | 0  | 0  | 0   |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |  |  |   |
| Metastases to lung  |  |  |   |
| subjects affected / exposed   | 0 / 28 (0.00%)                               | 0 / 24 (0.00%)                                   | 0 / 24 (0.00%)                              |
| occurrences causally related to treatment / all                     | 0 / 0  | 0 / 0  | 0 / 0                                       |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0  | 0 / 0                                       |
| Metastatic renal cell carcinoma                                     |  |  |   |
| subjects affected / exposed   | 0 / 28 (0.00%)                               | 0 / 24 (0.00%)                                   | 0 / 24 (0.00%)                              |
| occurrences causally related to treatment / all                     | 0 / 0  | 0 / 0  | 0 / 0                                       |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0  | 0 / 0                                       |
| Squamous cell carcinoma of the tongue                               |  |  |   |
| subjects affected / exposed   | 0 / 28 (0.00%)                               | 0 / 24 (0.00%)                                   | 0 / 24 (0.00%)                              |
| occurrences causally related to treatment / all                     | 0 / 0  | 0 / 0  | 0 / 0                                       |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0  | 0 / 0                                       |
| Injury, poisoning and procedural complications                      |  |  |   |
| Fall  |  |  |   |
| subjects affected / exposed   | 0 / 28 (0.00%)                               | 0 / 24 (0.00%)                                   | 0 / 24 (0.00%)                              |
| occurrences causally related to treatment / all                     | 0 / 0  | 0 / 0  | 0 / 0                                       |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0  | 0 / 0                                       |
| Subdural haematoma  |  |  |   |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 28 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                |                |                |
| Arteriosclerosis coronary artery                |                |                |                |
| subjects affected / exposed                     | 0 / 28 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac failure congestive                      |                |                |                |
| subjects affected / exposed                     | 0 / 28 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Coronary artery disease                         |                |                |                |
| subjects affected / exposed                     | 0 / 28 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Nervous system disorders                        |                |                |                |
| Neurodegenerative disorder                      |                |                |                |
| subjects affected / exposed                     | 0 / 28 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Eye disorders                                   |                |                |                |
| Amaurosis fugax                                 |                |                |                |
| subjects affected / exposed                     | 0 / 28 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Episcleritis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 28 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                      |                |                |                |
| Colitis ulcerative                              |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 28 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Crohn's disease                                 |                |                |                |
| subjects affected / exposed                     | 0 / 28 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders |                |                |                |
| Pulmonary embolism                              |                |                |                |
| subjects affected / exposed                     | 0 / 28 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory failure                             |                |                |                |
| subjects affected / exposed                     | 0 / 28 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                |                |
| Polymyalgia rheumatica                          |                |                |                |
| subjects affected / exposed                     | 0 / 28 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| Appendicitis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 28 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pneumonia                                       |                |                |                |
| subjects affected / exposed                     | 0 / 28 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Sepsis  |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 28 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Metabolism and nutrition disorders              |                |                |                |
| Adult failure to thrive                         |                |                |                |
| subjects affected / exposed                     | 0 / 28 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

| <b>Serious adverse events</b>                                       | NOR-107:<br>GI.1/GII.4<br>(50/150/500) µg,2- | NOR-107: GI.1/GII.4<br>(15/50/167) µg,1-<br>Dose | NOR-210:<br>GI.1/GII.4<br>(15/50/500) µg, 1- |
|---|--|--|--|
| Total subjects affected by serious adverse events                   |  |  |  |
| subjects affected / exposed   | 0 / 25 (0.00%)                               | 0 / 21 (0.00%)                                   | 1 / 24 (4.17%)                               |
| number of deaths (all causes)                                       | 0  | 0  | 0  |
| number of deaths resulting from adverse events                      | 0  | 0  | 0  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |  |  |  |
| Metastases to lung  |  |  |  |
| subjects affected / exposed   | 0 / 25 (0.00%)                               | 0 / 21 (0.00%)                                   | 0 / 24 (0.00%)                               |
| occurrences causally related to treatment / all                     | 0 / 0  | 0 / 0  | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0  | 0 / 0  |
| Metastatic renal cell carcinoma                                     |  |  |  |
| subjects affected / exposed   | 0 / 25 (0.00%)                               | 0 / 21 (0.00%)                                   | 0 / 24 (0.00%)                               |
| occurrences causally related to treatment / all                     | 0 / 0  | 0 / 0  | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0  | 0 / 0  |
| Squamous cell carcinoma of the tongue                               |  |  |  |
| subjects affected / exposed   | 0 / 25 (0.00%)                               | 0 / 21 (0.00%)                                   | 0 / 24 (0.00%)                               |
| occurrences causally related to treatment / all                     | 0 / 0  | 0 / 0  | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0  | 0 / 0  |
| Injury, poisoning and procedural complications                      |  |  |  |
| Fall  |  |  |  |
| subjects affected / exposed   | 0 / 25 (0.00%)                               | 0 / 21 (0.00%)                                   | 0 / 24 (0.00%)                               |
| occurrences causally related to treatment / all                     | 0 / 0  | 0 / 0  | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0  | 0 / 0  |
| Subdural haematoma  |  |  |  |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 25 (0.00%) | 0 / 21 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                |                |                |
| Arteriosclerosis coronary artery                |                |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%) | 0 / 21 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac failure congestive                      |                |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%) | 0 / 21 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Coronary artery disease                         |                |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%) | 0 / 21 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Nervous system disorders                        |                |                |                |
| Neurodegenerative disorder                      |                |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%) | 0 / 21 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Eye disorders                                   |                |                |                |
| Amaurosis fugax                                 |                |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%) | 0 / 21 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Episcleritis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%) | 0 / 21 (0.00%) | 1 / 24 (4.17%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                      |                |                |                |
| Colitis ulcerative                              |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 25 (0.00%) | 0 / 21 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Crohn's disease                                 |                |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%) | 0 / 21 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders |                |                |                |
| Pulmonary embolism                              |                |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%) | 0 / 21 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory failure                             |                |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%) | 0 / 21 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                |                |
| Polymyalgia rheumatica                          |                |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%) | 0 / 21 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| Appendicitis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%) | 0 / 21 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pneumonia                                       |                |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%) | 0 / 21 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Sepsis  |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 25 (0.00%) | 0 / 21 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Metabolism and nutrition disorders              |                |                |                |
| Adult failure to thrive                         |                |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%) | 0 / 21 (0.00%) | 0 / 24 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

| Serious adverse events  | NOR-204:<br>GI.1/GII.4<br>(15/50/500/15) µg, | NOR-204: GI.1/GII.4<br>(15/50/500) µg, 1-<br>Dose (Age: 60-94<br>Yrs) | NOR-204:<br>GI.1/GII.4<br>(15/50/500) µg, 1-<br>Dose (Age: 18-49 |
|---|--|---|--|
| Total subjects affected by serious adverse events                   |  |   |  |
| subjects affected / exposed   | 2 / 35 (5.71%)                               | 0 / 14 (0.00%)  | 5 / 39 (12.82%)  |
| number of deaths (all causes)                                       | 2  | 0   | 3  |
| number of deaths resulting from adverse events                      | 0  | 0   | 0  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |  |   |  |
| Metastases to lung  |  |   |  |
| subjects affected / exposed   | 0 / 35 (0.00%)                               | 0 / 14 (0.00%)  | 0 / 39 (0.00%)   |
| occurrences causally related to treatment / all                     | 0 / 0  | 0 / 0   | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0   | 0 / 0  |
| Metastatic renal cell carcinoma                                     |  |   |  |
| subjects affected / exposed   | 0 / 35 (0.00%)                               | 0 / 14 (0.00%)  | 0 / 39 (0.00%)   |
| occurrences causally related to treatment / all                     | 0 / 0  | 0 / 0   | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0   | 0 / 0  |
| Squamous cell carcinoma of the tongue                               |  |   |  |
| subjects affected / exposed   | 0 / 35 (0.00%)                               | 0 / 14 (0.00%)  | 1 / 39 (2.56%)   |
| occurrences causally related to treatment / all                     | 0 / 0  | 0 / 0   | 0 / 1  |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0   | 0 / 0  |
| Injury, poisoning and procedural complications                      |  |   |  |
| Fall  |  |   |  |
| subjects affected / exposed   | 0 / 35 (0.00%)                               | 0 / 14 (0.00%)  | 0 / 39 (0.00%)   |
| occurrences causally related to treatment / all                     | 0 / 0  | 0 / 0   | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0   | 0 / 0  |
| Subdural haematoma  |  |   |  |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 1 / 35 (2.86%) | 0 / 14 (0.00%) | 0 / 39 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                |                |                |
| Arteriosclerosis coronary artery                |                |                |                |
| subjects affected / exposed                     | 0 / 35 (0.00%) | 0 / 14 (0.00%) | 0 / 39 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac failure congestive                      |                |                |                |
| subjects affected / exposed                     | 0 / 35 (0.00%) | 0 / 14 (0.00%) | 1 / 39 (2.56%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Coronary artery disease                         |                |                |                |
| subjects affected / exposed                     | 0 / 35 (0.00%) | 0 / 14 (0.00%) | 0 / 39 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Nervous system disorders                        |                |                |                |
| Neurodegenerative disorder                      |                |                |                |
| subjects affected / exposed                     | 0 / 35 (0.00%) | 0 / 14 (0.00%) | 1 / 39 (2.56%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Eye disorders                                   |                |                |                |
| Amaurosis fugax                                 |                |                |                |
| subjects affected / exposed                     | 0 / 35 (0.00%) | 0 / 14 (0.00%) | 0 / 39 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Episcleritis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 35 (0.00%) | 0 / 14 (0.00%) | 0 / 39 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                      |                |                |                |
| Colitis ulcerative                              |                |                |                |



|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 35 (0.00%) | 0 / 14 (0.00%) | 0 / 39 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Crohn's disease                                 |                |                |                |
| subjects affected / exposed                     | 0 / 35 (0.00%) | 0 / 14 (0.00%) | 0 / 39 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders |                |                |                |
| Pulmonary embolism                              |                |                |                |
| subjects affected / exposed                     | 0 / 35 (0.00%) | 0 / 14 (0.00%) | 1 / 39 (2.56%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory failure                             |                |                |                |
| subjects affected / exposed                     | 1 / 35 (2.86%) | 0 / 14 (0.00%) | 0 / 39 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                |                |
| Polymyalgia rheumatica                          |                |                |                |
| subjects affected / exposed                     | 0 / 35 (0.00%) | 0 / 14 (0.00%) | 0 / 39 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| Appendicitis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 35 (0.00%) | 0 / 14 (0.00%) | 1 / 39 (2.56%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pneumonia                                       |                |                |                |
| subjects affected / exposed                     | 1 / 35 (2.86%) | 0 / 14 (0.00%) | 0 / 39 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Sepsis  |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 35 (0.00%) | 0 / 14 (0.00%) | 1 / 39 (2.56%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Metabolism and nutrition disorders              |                |                |                |
| Adult failure to thrive                         |                |                |                |
| subjects affected / exposed                     | 1 / 35 (2.86%) | 0 / 14 (0.00%) | 0 / 39 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

| <b>Serious adverse events</b>                                       | NOR-204:<br>GI.1/GII.4<br>(15/50/500/15) µg -<br>MPL 15 µg, 2-Dose | NOR-204: GI.1/GII.4<br>(15/50/500) µg, 2-<br>Dose |  |
|---|--|---|--|
| Total subjects affected by serious adverse events                   |  |   |  |
| subjects affected / exposed   | 2 / 29 (6.90%)   | 2 / 42 (4.76%)                                    |  |
| number of deaths (all causes)                                       | 1  | 0   |  |
| number of deaths resulting from adverse events                      | 0  | 0   |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |  |   |  |
| Metastases to lung  |  |   |  |
| subjects affected / exposed   | 1 / 29 (3.45%)   | 0 / 42 (0.00%)                                    |  |
| occurrences causally related to treatment / all                     | 0 / 1  | 0 / 0   |  |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0   |  |
| Metastatic renal cell carcinoma                                     |  |   |  |
| subjects affected / exposed   | 1 / 29 (3.45%)   | 0 / 42 (0.00%)                                    |  |
| occurrences causally related to treatment / all                     | 0 / 1  | 0 / 0   |  |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0   |  |
| Squamous cell carcinoma of the tongue                               |  |   |  |
| subjects affected / exposed   | 0 / 29 (0.00%)   | 0 / 42 (0.00%)                                    |  |
| occurrences causally related to treatment / all                     | 0 / 0  | 0 / 0   |  |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0   |  |
| Injury, poisoning and procedural complications                      |  |   |  |
| Fall  |  |   |  |
| subjects affected / exposed   | 0 / 29 (0.00%)   | 1 / 42 (2.38%)                                    |  |
| occurrences causally related to treatment / all                     | 0 / 0  | 0 / 1   |  |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0   |  |
| Subdural haematoma  |  |   |  |

|   |                |                |  |
|---|----------------|----------------|--|
| subjects affected / exposed                     | 0 / 29 (0.00%) | 1 / 42 (2.38%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Cardiac disorders                               |                |                |  |
| Arteriosclerosis coronary artery                |                |                |  |
| subjects affected / exposed                     | 0 / 29 (0.00%) | 1 / 42 (2.38%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Cardiac failure congestive                      |                |                |  |
| subjects affected / exposed                     | 0 / 29 (0.00%) | 0 / 42 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Coronary artery disease                         |                |                |  |
| subjects affected / exposed                     | 0 / 29 (0.00%) | 1 / 42 (2.38%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Nervous system disorders                        |                |                |  |
| Neurodegenerative disorder                      |                |                |  |
| subjects affected / exposed                     | 0 / 29 (0.00%) | 0 / 42 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Eye disorders                                   |                |                |  |
| Amaurosis fugax                                 |                |                |  |
| subjects affected / exposed                     | 1 / 29 (3.45%) | 0 / 42 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Episcleritis                                    |                |                |  |
| subjects affected / exposed                     | 0 / 29 (0.00%) | 0 / 42 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Gastrointestinal disorders                      |                |                |  |
| Colitis ulcerative                              |                |                |  |

|   |                |                |  |
|---|----------------|----------------|--|
| subjects affected / exposed                     | 0 / 29 (0.00%) | 0 / 42 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Crohn's disease                                 |                |                |  |
| subjects affected / exposed                     | 0 / 29 (0.00%) | 0 / 42 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Respiratory, thoracic and mediastinal disorders |                |                |  |
| Pulmonary embolism                              |                |                |  |
| subjects affected / exposed                     | 0 / 29 (0.00%) | 0 / 42 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Respiratory failure                             |                |                |  |
| subjects affected / exposed                     | 0 / 29 (0.00%) | 0 / 42 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Musculoskeletal and connective tissue disorders |                |                |  |
| Polymyalgia rheumatica                          |                |                |  |
| subjects affected / exposed                     | 0 / 29 (0.00%) | 0 / 42 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Infections and infestations                     |                |                |  |
| Appendicitis                                    |                |                |  |
| subjects affected / exposed                     | 0 / 29 (0.00%) | 0 / 42 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Pneumonia                                       |                |                |  |
| subjects affected / exposed                     | 0 / 29 (0.00%) | 0 / 42 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Sepsis  |                |                |  |

|   |                |                |  |
|---|----------------|----------------|--|
| subjects affected / exposed                     | 0 / 29 (0.00%) | 0 / 42 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Metabolism and nutrition disorders              |                |                |  |
| Adult failure to thrive                         |                |                |  |
| subjects affected / exposed                     | 0 / 29 (0.00%) | 0 / 42 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |

Frequency threshold for reporting non-serious adverse events: 5 %

|   |   |  |   |
|---|---|--|---|
| <b>Non-serious adverse events</b>                     | NOR-107:<br>GI.1/GII.4<br>(15/50/500) µg- | NOR-107: GI.1/GII.4<br>(15/15/500) µg-<br>MPL 50 µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(50/50/500) µg- |
| Total subjects affected by non-serious adverse events |   |  |   |
| subjects affected / exposed                           | 0 / 27 (0.00%)                            | 0 / 25 (0.00%)   | 0 / 19 (0.00%)                            |

|   |   |  |   |
|---|---|--|---|
| <b>Non-serious adverse events</b>                     | NOR-107:<br>GI.1/GII.4<br>(15/15/500) µg- | NOR-107: GI.1/GII.4<br>(15/50/500) µg-<br>MPL 15 µg,1-Dose | NOR-107:<br>GI.1/GII.4<br>(50/50/500) µg- |
| Total subjects affected by non-serious adverse events |   |  |   |
| subjects affected / exposed                           | 0 / 27 (0.00%)                            | 0 / 23 (0.00%)   | 0 / 27 (0.00%)                            |

|   |   |  |   |
|---|---|--|---|
| <b>Non-serious adverse events</b>                     | NOR-107:<br>GI.1/GII.4<br>(15/15/500) µg,1- | NOR-107: GI.1/GII.4<br>(50/50/500) µg,1-<br>Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/500) µg,1- |
| Total subjects affected by non-serious adverse events |   |  |   |
| subjects affected / exposed                           | 0 / 22 (0.00%)                              | 0 / 25 (0.00%)                                   | 0 / 28 (0.00%)                              |

|   |  |  |   |
|---|--|--|---|
| <b>Non-serious adverse events</b>                     | NOR-107:<br>GI.1/GII.4<br>(50/150/500) µg,1- | NOR-107: GI.1/GII.4<br>(15/50/167) µg,1-<br>Dose | NOR-107:<br>GI.1/GII.4<br>(15/50/500) µg,2- |
| Total subjects affected by non-serious adverse events |  |  |   |
| subjects affected / exposed                           | 0 / 28 (0.00%)                               | 0 / 24 (0.00%)                                   | 0 / 24 (0.00%)                              |

|                                   |  |  |  |
|-----------------------------------|--|--|--|
| <b>Non-serious adverse events</b> | NOR-107:<br>GI.1/GII.4<br>(50/150/500) µg,2- | NOR-107: GI.1/GII.4<br>(15/50/167) µg,1-<br>Dose | NOR-210:<br>GI.1/GII.4<br>(15/50/500) µg, 1- |
|-----------------------------------|--|--|--|

|  |                |                |                |
|--|----------------|----------------|----------------|
| Total subjects affected by non-serious adverse events<br>subjects affected / exposed | 0 / 25 (0.00%) | 0 / 21 (0.00%) | 0 / 24 (0.00%) |
|--|----------------|----------------|----------------|

|  |  |   |  |
|--|--|---|--|
| <b>Non-serious adverse events</b>  | NOR-204:<br>GI.1/GII.4<br>(15/50/500/15) µg, | NOR-204: GI.1/GII.4<br>(15/50/500) µg, 1-<br>Dose (Age: 60-94<br>Yrs) | NOR-204:<br>GI.1/GII.4<br>(15/50/500) µg, 1-<br>Dose (Age: 18-49 |
| Total subjects affected by non-serious adverse events<br>subjects affected / exposed | 0 / 35 (0.00%)                               | 0 / 14 (0.00%)  | 0 / 39 (0.00%)   |

|  |  |   |  |
|--|--|---|--|
| <b>Non-serious adverse events</b>  | NOR-204:<br>GI.1/GII.4<br>(15/50/500/15) µg -<br>MPL 15 µg, 2-Dose | NOR-204: GI.1/GII.4<br>(15/50/500) µg, 2-<br>Dose |  |
| Total subjects affected by non-serious adverse events<br>subjects affected / exposed | 0 / 29 (0.00%)   | 0 / 42 (0.00%)                                    |  |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported